var title_f34_16_35072="Flurbiprofen: Pediatric drug information";
var content_f34_16_35072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurbiprofen: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/61/42962?source=see_link\">",
"       Flurbiprofen (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/46/7911?source=see_link\">",
"       Flurbiprofen (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13318 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35072=[""].join("\n");
var outline_f34_16_35072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/61/42962?source=related_link\">",
"      Flurbiprofen (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/46/7911?source=related_link\">",
"      Flurbiprofen (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_16_35073="Patient with SGD";
var content_f34_16_35073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with neutrophil-specific granule deficiency (SGD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 9-year-old boy with SGD presented for evaluation with severe, large bacterial abscesses of several months duration. This patient was described in detail by Gallin, JI, et al. Blood 1982; 59:1317.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Robert L Roberts.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35073=[""].join("\n");
var outline_f34_16_35073=null;
var title_f34_16_35074="Fibroid embolization 2a";
var content_f34_16_35074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62884%7EOBGYN%2F74642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62884%7EOBGYN%2F74642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibroid embolization 2a",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing superselective catheter position in the right uterine artery via left femoral arterial approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibroid embolization 2b",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing embolic particles being released from the catheter and into the uterine arterial branches supplying the fibroid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35074=[""].join("\n");
var outline_f34_16_35074=null;
var title_f34_16_35075="Oxiconazole: Patient drug information";
var content_f34_16_35075=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxiconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7827?source=see_link\">",
"     see \"Oxiconazole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxistat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oxistat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702651",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxiconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake lotion well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10936 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35075=[""].join("\n");
var outline_f34_16_35075=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204543\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013537\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013536\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013541\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013542\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013544\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013539\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013540\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013545\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013546\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7827?source=related_link\">",
"      Oxiconazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_16_35076="Epiploic appendagitis";
var content_f34_16_35076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epiploic appendagitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35076/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35076/contributors\">",
"     Andres Gelrud, MD, MMSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35076/contributors\">",
"     Andr&eacute;s C&aacute;rdenas, MD, MMSc, AGAF",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35076/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35076/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35076/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35076/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35076/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/16/35076/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiploic appendagitis (EA), also known as appendicitis epiploica, hemorrhagic epiploitis, epiplopericolitis, or appendagitis, is a benign and self-limited condition of the epiploic appendages that occurs secondary to torsion or spontaneous venous thrombosis of a draining vein [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. EA occurs most commonly in the second to fifth decades of life; the mean age in several reports was approximately 38 years and there was a similar incidence among men and women. Complete resolution without surgical intervention usually occurs between 3 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Inaccurate diagnosis can lead to unnecessary hospitalizations, antibiotic therapy, and surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiploic appendages are small outpouchings of fat-filled, serosa-covered structures present on the external surface of the colon projecting into the peritoneal cavity. The appendages are situated along the entire colon and are more abundant and larger in the transverse and sigmoid colon. Approximately 50 to 100 appendages are present in the colon of an average person. They are usually rudimentary at the base of the appendix [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epiploic appendages vary considerably in size, shape, and contour. For unclear reasons, they are largest and most prominent in obese persons and in those who have recently lost weight [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. The average length of the epiploic appendage is 3 cm, although they are occasionally up to 15 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/10\">",
"     10",
"    </a>",
"    ]. They are presumed to serve a protective and defensive mechanism similar to that offered by the greater omentum. They may also act as a protective cushion during peristalsis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each appendage encloses small branches of the circular artery and vein that supply the corresponding segment of the colon. Subserosal lymphatic channels either terminate in a lymph node within an appendage or loop through its base en route to mesenteric nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiploic appendagitis (EA) is usually caused by torsion, which occurs when the appendage is abnormally long and large. The vein, which is longer than the artery by virtue of its tortuous course, alters the anatomy such that the pedicle is predisposed to twisting. Spontaneous venous thrombosis of a draining vein can also predispose to twisting of the appendage pedicle. Gradual torsion of the appendages can result in chronic inflammation with minimal or no symptoms. In contrast, acute strangulation is associated with the development of symptoms.",
"   </p>",
"   <p>",
"    Symptomatic EA can arise on any segment of the colon. The affected site was in the sigmoid colon or cecum in 75 percent of 156 patients in a retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/2\">",
"     2",
"    </a>",
"    ]. In another report of 58 patients, the locations were the sigmoid (48 percent), descending (28 percent), transverse (7 percent), and ascending colon (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are other less common conditions affecting the epiploic appendices. They can slide into a femoral, umbilical, or inguinal hernia sac where they may remain without causing symptoms or (less commonly) incarcerate with or without torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. The appendices can also calcify, cast off, and lie free as foreign bodies (corpora aliena) in the peritoneal cavity or become surrounded by omental adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/13\">",
"     13",
"    </a>",
"    ]. Epiploic appendages are thought to represent the most frequent source of intraperitoneal loose bodies, which are usually found in the pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/14\">",
"     14",
"    </a>",
"    ]. These may become secondarily attached elsewhere in the abdomen and can be confused with a neoplastic process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients most commonly present with acute abdominal pain. Symptoms can mimic an acute abdomen, frequently leading patients to be misdiagnosed as having acute appendicitis or diverticulitis. Appetite and bowel function are usually unchanged; nausea and vomiting are rare.",
"   </p>",
"   <p>",
"    On physical examination patients usually do not appear to be seriously ill and are afebrile. There is localized pain in the affected area, more often in the left lower than right lower quadrant. Rebound tenderness is usually not present [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/15\">",
"     15",
"    </a>",
"    ]. A mass is palpable in 10 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/16\">",
"     16",
"    </a>",
"    ]. The remainder of the examination is usually unremarkable.",
"   </p>",
"   <p>",
"    Laboratory tests are useful for excluding other causes of similar symptoms. There are no pathognomonic diagnostic laboratory findings. The white blood count with differential and erythrocyte sedimentation rate are normal or only moderately elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/4,17\">",
"     4,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiploic appendagitis (EA) should be considered in the differential diagnosis of patients presenting with localized lower abdominal pain without associated leukocytosis or fever (",
"    <a class=\"graphic graphic_table graphicRef57034 \" href=\"UTD.htm?11/38/11883\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/13,18,19\">",
"     13,18,19",
"    </a>",
"    ]. EA has been reported in 2 to 7 percent of patients in which a clinical suspicion of diverticulitis was entertained and in 0.3 to 1 percent of patients suspected of having appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ]. The diagnosis should also be considered when exploration of the abdomen fails to reveal any of the more common causes an acute abdomen. When the diagnosis is not made before the patient undergoes surgery, the inflamed appendage is ligated and resected [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early radiologic examination with an abdominal computed tomography (CT) scan is key in making the diagnosis. This was illustrated in a retrospective study of 19 cases of EA presenting over a four-year period in which a diagnosis was made by abdominal CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/6\">",
"     6",
"    </a>",
"    ]. Prior to having the abdominal CT scan performed, two-thirds of patients were suspected of having either appendicitis or diverticulitis.",
"   </p>",
"   <p>",
"    CT findings are virtually pathognomonic for EA while excluding other causes of abdominal pain. The appendices epiploica are usually not seen on CT scan unless they are surrounded by a sufficient amount of intraperitoneal fluid such as ascites or hemoperitoneum. The classic finding is a 2 to 3 cm, oval-shaped, fat density, paracolic mass with thickened peritoneal lining and peri-appendageal fat stranding [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/4,19,23-27\">",
"     4,19,23-27",
"    </a>",
"    ]. A high-attenuated central dot within the inflamed appendage that corresponds to a thrombosed draining appendageal vein is occasionally evident [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/4,21\">",
"     4,21",
"    </a>",
"    ]. MRI findings of EA have not been well studied but appear to correlate with CT findings [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EA can also be diagnosed on abdominal ultrasonography in both gray-scale and color Doppler, an approach probably best suited for patients with a thin body habitus seen at centers with experience in sonographic imaging of the colon. The inflamed appendage appears as a non-compressible, solid, hyperechoic ovoid mass with a subtle hypoechoic rim located at the point of maximal tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/4\">",
"     4",
"    </a>",
"    ]. The inflamed fatty mass is fixed to the colon and often also to the parietal peritoneum during inspiration and expiration. Doppler studies typically reveal absence of blood flow in the appendage [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/5,25,29,30\">",
"     5,25,29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32154?source=see_link\">",
"     \"Transabdominal ultrasonography of the small and large intestine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contrast enhanced ultrasound may be helpful to confirm the diagnosis of EA in equivocal cases when CT is not readily available. In a retrospective study of 15 cases of EA over a two-year period, masses noted on contrast enhanced ultrasound showed a central area of no enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiploic appendagitis (EA) is a benign and self-limiting condition in which the abdominal computed tomography (CT) scan appearance can lead to a confident diagnosis. Patients can be managed conservatively with oral antiinflammatory medications and occasionally a short course of opiates [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/3,4,6,32,33\">",
"     3,4,6,32,33",
"    </a>",
"    ]. Antiinflammatories provide analgesia but probably do not modify the disease. Although there are no strict guidelines for therapy, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (600 mg po every eight hours for four to six days) and Tylenol #3",
"    <span class=\"nowrap\">",
"     (",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"      acetaminophen",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"      codeine",
"     </a>",
"    </span>",
"    <span class=\"nowrap\">",
"     300/30)",
"    </span>",
"    every six hours as needed for four to six days. Most patients respond to these measures in about four to seven days. Patients should be advised to seek medical attention if symptoms worsen after two days (such as with the development of high fever, progressive pain, nausea, vomiting, or inability to tolerate an oral diet). As a general rule, patients do not require hospitalization or antibiotics.",
"   </p>",
"   <p>",
"    Complications are uncommon. Inflamed appendages can adhere to the abdominal wall or other viscera predisposing to intestinal obstruction and intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35076/abstract/34\">",
"     34",
"    </a>",
"    ]. Inflamed and necrotic appendages can also rarely progress to abscess formation for which surgery is usually indicated. The risk of recurrence has not been described but is probably very low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epiploic appendagitis (EA), also known as appendicitis epiploica, hemorrhagic epiploitis, epiplopericolitis, or appendagitis, is a benign and self-limited condition of the epiploic appendages that occurs secondary to torsion or spontaneous venous thrombosis of a draining vein. It usually occurs when the appendage is abnormally long and large. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients most commonly present with acute abdominal pain. Symptoms can mimic an acute abdomen, frequently leading patients to be misdiagnosed as having acute appendicitis or diverticulitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EA should be considered in the differential diagnosis of patients presenting with localized lower abdominal pain without associated leukocytosis or fever (",
"      <a class=\"graphic graphic_table graphicRef57034 \" href=\"UTD.htm?11/38/11883\">",
"       table 1",
"      </a>",
"      ). Early radiologic examination with an abdominal computed tomography (CT) scan is key in making the diagnosis and potentially avoiding unnecessary surgery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with EA confirmed by CT scan be managed conservatively with oral antiinflammatory medications and occasionally a short course of opiates (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Most patients respond to these measures in about four to seven days. Patients should be advised to seek medical attention if symptoms worsen after two days (such as with the development of high fever, progressive pain, nausea, vomiting, or inability to tolerate an oral diet). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/1\">",
"      Pines BR, Beller J. Primary torsion and infarction of the appendices epiploicae. Arch Surg 1941; 42:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/2\">",
"      DOCKERTY MB, LYNN TE, WAUGH JM. A clinicopathologic study of the epiploic appendages. Surg Gynecol Obstet 1956; 103:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/3\">",
"      Desai HP, Tripodi J, Gold BM, Burakoff R. Infarction of an epiploic appendage. Review of the literature. J Clin Gastroenterol 1993; 16:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/4\">",
"      Rioux M, Langis P. Primary epiploic appendagitis: clinical, US, and CT findings in 14 cases. Radiology 1994; 191:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/5\">",
"      Lee YC, Wang HP, Huang SP, et al. Gray-scale and color Doppler sonographic diagnosis of epiploic appendagitis. J Clin Ultrasound 2001; 29:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/6\">",
"      Legome EL, Belton AL, Murray RE, et al. Epiploic appendagitis: the emergency department presentation. J Emerg Med 2002; 22:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/7\">",
"      Rao PM, Rhea JT, Wittenberg J, Warshaw AL. Misdiagnosis of primary epiploic appendagitis. Am J Surg 1998; 176:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/8\">",
"      Patterson DC. Appendices epiploicae and their surgical significance with report of three cases. N Engl J Med 1933; 209:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/9\">",
"      Ghahremani GG, White EM, Hoff FL, et al. Appendices epiploicae of the colon: radiologic and pathologic features. Radiographics 1992; 12:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/10\">",
"      Linkenfeld F. Deutsche Ztschr f Chir 1908; 92:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/11\">",
"      Macari M, Laks S, Hajdu C, Babb J. Caecal epiploic appendagitis: an unlikely occurrence. Clin Radiol 2008; 63:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/12\">",
"      Adler JE. Torsion of an appendix epiploica in a bilocular hernial sac. Lancet 1908; 172:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/13\">",
"      Klingenstein P. Some phases of the pathology of the appendices epiploicae. Surg Gynecol Obstet 1924; 38:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/14\">",
"      ROSS JA, McQUEEN A. Peritoneal loose bodies. Br J Surg 1948; 35:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/15\">",
"      McGeer PL, McKenzie AD. Strangulation of the appendix epiploica: A series of 11 cases. Can J Surg 1960; 3:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/16\">",
"      Shehan JJ, Organ C, Sullivan JF. Infarction of the appendices epiploicae. Am J Gastroenterol 1966; 46:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/17\">",
"      Carmichael DH, Organ CH Jr. Epiploic disorders. Conditions of the epiploic appendages. Arch Surg 1985; 120:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/18\">",
"      Moll&agrave; E, Ripoll&eacute;s T, Mart&iacute;nez MJ, et al. Primary epiploic appendagitis: US and CT findings. Eur Radiol 1998; 8:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/19\">",
"      Horton KM, Corl FM, Fishman EK. CT evaluation of the colon: inflammatory disease. Radiographics 2000; 20:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/20\">",
"      Rao PM, Rhea JT, Novelline RA, et al. Effect of computed tomography of the appendix on treatment of patients and use of hospital resources. N Engl J Med 1998; 338:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/21\">",
"      Rao PM, Wittenberg J, Lawrason JN. Primary epiploic appendagitis: evolutionary changes in CT appearance. Radiology 1997; 204:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/22\">",
"      Patel VG, Rao A, Williams R, et al. Cecal epiploic appendagitis: a diagnostic and therapeutic dilemma. Am Surg 2007; 73:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/23\">",
"      Rao PM. CT of diverticulitis and alternative conditions. Semin Ultrasound CT MR 1999; 20:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/24\">",
"      Singh AK, Gervais DA, Hahn PF, et al. CT appearance of acute appendagitis. AJR Am J Roentgenol 2004; 183:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/25\">",
"      Deceuninck A, Danse E. Primary epiploic appendagitis: US and CT findings. JBR-BTR 2006; 89:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/26\">",
"      Ng KS, Tan AG, Chen KK, et al. CT features of primary epiploic appendagitis. Eur J Radiol 2006; 59:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/27\">",
"      Subramaniam R. Acute appendagitis: emergency presentation and computed tomographic appearances. Emerg Med J 2006; 23:e53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/28\">",
"      Sirvanci M, Balci NC, Karaman K, et al. Primary epiploic appendagitis: MRI findings. Magn Reson Imaging 2002; 20:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/29\">",
"      van Breda Vriesman AC, Puylaert JB. Epiploic appendagitis and omental infarction: pitfalls and look-alikes. Abdom Imaging 2002; 27:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/30\">",
"      Danse EM, Van Beers BE, Baudrez V, et al. Epiploic appendagitis: color Doppler sonographic findings. Eur Radiol 2001; 11:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/31\">",
"      G&ouml;rg C, Egbring J, Bert T. Contrast-enhanced ultrasound of epiploic appendagitis. Ultraschall Med 2009; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/32\">",
"      Legome EL, Sims C, Rao PM. Epiploic appendagitis: adding to the differential of acute abdominal pain. J Emerg Med 1999; 17:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/33\">",
"      Vinson DR. Epiploic appendagitis: a new diagnosis for the emergency physician. Two case reports and a review. J Emerg Med 1999; 17:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35076/abstract/34\">",
"      Puppala AR, Mustafa SG, Moorman RH, Howard CH. Small bowel obstruction due to disease of epiploic appendage. Am J Gastroenterol 1981; 75:382.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2587 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-5203FA14AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35076=[""].join("\n");
var outline_f34_16_35076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2587|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/38/11883\" title=\"table 1\">",
"      Differential dx appendagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32154?source=related_link\">",
"      Transabdominal ultrasonography of the small and large intestine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_16_35077="Cyanocobalamin (vitamin B12): Patient drug information";
var content_f34_16_35077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyanocobalamin (vitamin B12): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/10/28838?source=see_link\">",
"     see \"Cyanocobalamin (vitamin B12): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/37/1622?source=see_link\">",
"     see \"Cyanocobalamin (vitamin B12): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ener-B&reg; [OTC];",
"     </li>",
"     <li>",
"      Nascobal&reg;;",
"     </li>",
"     <li>",
"      Twelve Resin-K [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691430",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low vitamin B",
"       <sub>",
"        12",
"       </sub>",
"       .",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cyanocobalamin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694183",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Under the tongue (sublingual):",
"        </span>",
"       </b>",
"       Place under your tongue and let melt. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prime pump by squeezing it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your spray use with your doctor at each visit. Read and follow the facts on how to use the spray. Make sure you use the spray the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 1 hour before or after eating or drinking hot foods or liquids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or under the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11479 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35077=[""].join("\n");
var outline_f34_16_35077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017235\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017234\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017239\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017240\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017242\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017237\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017238\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017243\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017244\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/10/28838?source=related_link\">",
"      Cyanocobalamin (vitamin B12): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/37/1622?source=related_link\">",
"      Cyanocobalamin (vitamin B12): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_16_35078="IgG subclasses: Physical properties, genetics, and biologic functions";
var content_f34_16_35078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   IgG subclasses: Physical properties, genetics, and biologic functions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35078/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35078/contributors\">",
"     J Keith Lemmon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35078/contributors\">",
"     Alan P Knutsen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35078/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35078/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35078/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35078/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/16/35078/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin G (IgG) can be subdivided into four subclasses: IgG1, IgG2, IgG3, and IgG4 [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. This topic will review the structure, normal serum concentrations, genetics, and biologic properties of IgG subclasses. Disorders associated with increased or decreased levels of IgG subclasses are mentioned briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"     \"IgG subclass deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROPERTIES OF IgG SUBCLASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structure, genetics, and function of the IgG subclasses are reviewed in this section. Detailed discussions of these topics as they apply to immunoglobulins in general are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=see_link\">",
"     \"Structure of immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22335778\">",
"    <span class=\"h2\">",
"     Structures and physical properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the four IgG subclasses is present in the serum in monomeric form. The tertiary structure of the molecules is similar, although they differ in the location and number of interchain disulfide bonds (",
"    <a class=\"graphic graphic_figure graphicRef61274 \" href=\"UTD.htm?20/41/21149\">",
"     figure 1",
"    </a>",
"    ). All four IgG subclasses cross the placenta.",
"   </p>",
"   <p>",
"    The determination of immunoglobulin class",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subclass is based upon differences in the heavy chain constant (CH) regions (",
"    <a class=\"graphic graphic_figure graphicRef71452 \" href=\"UTD.htm?19/30/19950\">",
"     figure 2",
"    </a>",
"    ). Functional differences among the subclasses arise from structural variation in both the Fc regions and in the hinge regions (the area where the variable or Fab regions are joined to the Fc region) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Fc region of each IgG subclass has a distinct affinity for phagocyte membrane Fc receptors. The binding of IgG molecules to these receptors is important for initiating phagocytosis. IgG1 and IgG3 bind Fc receptors more effectively than IgG2 and IgG4 [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Biological functions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The hinge regions of antibody molecules allow for rotation and flexion of the Fab arms. The degree of flexibility depends upon the amount of inter-heavy chain disulfide bonds present within the hinge [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/5\">",
"     5",
"    </a>",
"    ]. In decreasing order, the relative flexibility of the hinge regions of the IgG subclasses is as follows: IgG3 &gt; IgG1 &gt; IgG4 &gt; IgG2 [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/7\">",
"     7",
"    </a>",
"    ]. The flexibility of IgG3 may contribute to its greater ability to trigger effector functions. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Biological functions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An IgG molecule is composed of two identical heavy (H) chains and two identical light (L) chains, which usually results in two identical antigen binding sites on the Fab arms. However, IgG4 antibodies have unique structural and functional properties and undergo &ldquo;half antibody exchange,&rdquo; resulting in recombined antibodies composed of two different binding specificities [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/8\">",
"     8",
"    </a>",
"    ]. A large fraction of IgG4 molecules exchange H-L dimer partners resulting in a hybrid antibody that contains two different Fab arms with different antigen specificities. Although this antibody can only bind monovalently, it is capable of cross-linking two different antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/9\">",
"     9",
"    </a>",
"    ]. The functional significance of this characteristic is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3396734\">",
"    <span class=\"h2\">",
"     Normal serum concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subclasses are named according to their abundance in the serum [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgG1 comprises 60 to 70 percent of total IgG",
"     </li>",
"     <li>",
"      IgG2 comprises 20 to 30 percent",
"     </li>",
"     <li>",
"      IgG3 comprises 5 to 8 percent",
"     </li>",
"     <li>",
"      IgG4 comprises 1 to 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because IgG1 accounts for the majority of total serum IgG, deficiencies in IgG1 often result in overall hypogammaglobulinemia. In contrast, deficiencies of the other subclasses can be accompanied by normal levels of total IgG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"     \"IgG subclass deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal levels of the IgG subclasses are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef50967 \" href=\"UTD.htm?6/48/6925\">",
"     table 1",
"    </a>",
"    ). Although all IgG subclasses are transported through the placenta, IgG2 is not as well transported as the other subclasses, so that newborns have lower levels of IgG2 antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/11\">",
"     11",
"    </a>",
"    ]. The levels of each of the IgG subclasses rise at different rates during development. Adult IgG1 levels are present by five years of age; however, adult levels of IgG2, IgG3, and IgG4 are not achieved until adolescence (",
"    <a class=\"graphic graphic_figure graphicRef58666 \" href=\"UTD.htm?30/0/30734\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The measurement of IgG subclass levels is complicated by several factors, including normal variation with age and the use of different methodologies. These factors are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link&amp;anchor=H12#H12\">",
"     \"IgG subclass deficiency\", section on 'Measurement techniques and normal levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3397212\">",
"    <span class=\"h2\">",
"     Half-lives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The half-life of IgG3, which is relatively susceptible to proteolytic enzymes, is about nine days, whereas the half-lives of IgG1, IgG2, and IgG4 are approximately 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heavy chain constant (CH) regions of an immunoglobulin molecule determine its class and subclass. The amino acid sequences of the various IgG subclasses are 90 to 95 percent homologous [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/14\">",
"     14",
"    </a>",
"    ]. The CH regions are encoded by C gene segments clustered on chromosome 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Each of the four subclasses has a corresponding C gene segment that encodes its CH regions. As an example, the gene segment C&gamma;2 encodes the CH regions of IgG2 molecules and C&gamma;3 encodes the corresponding regions of IgG3 molecules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3396833\">",
"    <span class=\"h2\">",
"     Allotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the C genes provide additional amino acid variation in the sequence composition of IgG subclass proteins. These mutations are inherited in an autosomal pattern and can serve as genetic markers, or allotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, allotyping is used to distinguish an antibody of a particular subclass encoded by allele \"a\" from an antibody of the same isotype encoded by allele \"b\". Allotype nomenclature designates these antigenic markers by class, subclass, the letter \"m\", and then the allele in parentheses. As an example, G2m(n) is the n allele of IgG2 molecule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=see_link&amp;anchor=H13#H13\">",
"     \"Structure of immunoglobulins\", section on 'Antigenic differences among antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence that IgG subclass levels are influenced by allotypes and allotype combinations under normal conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, individuals of IgG allotype G3m(5) have twice the IgG3 levels as those with IgGm(21) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allotypes can vary markedly among healthy human populations from different geographical regions [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/19\">",
"     19",
"    </a>",
"    ]. It has been hypothesized that antibodies of certain allotypes may confer superior protection to pathogens indigenous to specific regions [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BIOLOGICAL FUNCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biologic functions of the IgG subclasses include opsonization and complement activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2280352\">",
"    <span class=\"h2\">",
"     Opsonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG1, IgG2, and IgG3 are important for opsonization of microbes by phagocytes. Opsonization refers to the binding of antibodies to the surfaces of a microbe or foreign particle in order to facilitate phagocytosis by neutrophils or macrophages. Both antibodies and complement proteins can act as opsonins. Immunoglobulin molecules interact with microbes through their Fab portions, and bind to phagocytes through the Fc portion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link&amp;anchor=H2#H2\">",
"     \"Function and clinical applications of immunoglobulins\", section on 'Functions of the Ig variable region'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link&amp;anchor=H3#H3\">",
"     \"Neutrophil functions other than movement\", section on 'Opsonins and opsonin receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the other subclasses, IgG4 has low affinity for Fc receptors and C1q and thus minimal ability to activate cells or initiate complement activation. In addition, IgG4 antibodies may undergo Fab arm exchange resulting in two different antigen specific antibodies. This results in loss of IgG4 antibodies to cross-link antigens and form immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2280359\">",
"    <span class=\"h2\">",
"     Complement activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various subclasses differ in their ability to bind C1q and activate the classical complement pathway. IgG1 and IgG3 fix C1q most effectively while IgG2 does so weakly. IgG4 does not bind complement at all [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link&amp;anchor=H2#H2\">",
"     \"Complement pathways\", section on 'Classical pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role in specific types of infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody responses to certain types of pathogens are predominantly comprised of molecules of a specific subclass, which is referred to as IgG subclass restriction. Specifically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibody responses to bacterial polysaccharide antigens, such as the capsular antigens of pneumococcus, are composed mainly of IgG2 molecules [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibody responses to protein antigens and viral antigens are composed predominantly of IgG1 and IgG3 [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The biologic role of IgG4 is incompletely understood, although the finding that antibody responses to chronic schistosomiasis and filariases are primarily composed of IgG4 molecules suggests that IgG4 may play a role in the immune response against parasitic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Total and antigen-specific IgG3 and IgG4 were elevated in Indian children with visceral leishmaniasis [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3397374\">",
"    <span class=\"h1\">",
"     DISORDERS ASSOCIATED WITH ELEVATED SUBCLASS LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markedly elevated levels of any of the IgG subclasses, often with diminution of the others, is characteristic of the IgG gammopathies, including multiple myeloma or benign monoclonal IgG paraproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased IgG4 levels have been reported in a wide variety of disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG4-related systemic disease (IgG4-RSD) is a rare and newly-recognized entity comprised of a collection of disorders that share specific pathologic, serologic, and clinical features. The commonly shared features include tumor-like swelling of involved organs, with a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells and variable degrees of fibrosis, elevated serum levels of IgG4, and responsiveness to glucocorticoids, particularly in early stages of disease. Two major presentations of this condition are autoimmune pancreatitis and a syndrome of sialadenitis and salivary gland enlargement similar to but distinct from Sj&ouml;gren&rsquo;s syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13178?source=see_link\">",
"       \"Overview of IgG4-related disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with allergic disorders, such as atopic dermatitis, may demonstrate elevated levels of IgG4, probably due to prolonged allergen stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients receiving allergen immunotherapy develop increased levels of allergen-specific IgG4. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=see_link&amp;anchor=H6#H6\">",
"       \"Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms\", section on 'Blocking IgG4 antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased levels of IgG4 were described in idiopathic membranous nephropathy, in association with increased IL-10 and IL-13 mRNA expression [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link&amp;anchor=H5#H5\">",
"       \"Causes and diagnosis of membranous nephropathy\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of pulmonary disorders including Loeffler&rsquo;s syndrome, leiomyosarcoma, periarteritis nodosa, and mycosis fungoides, have been associated with elevated IgG4 levels [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated IgG4 levels have also been reported in rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35078/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"       \"Autoimmune pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3397367\">",
"    <span class=\"h1\">",
"     DISORDERS ASSOCIATED WITH REDUCED SUBCLASS LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased levels of IgG subclasses are seen in the normal population, but can also be associated with increased frequency and severity of infections, particularly of the upper and lower respiratory tract. IgG subclass deficiency is considered to be a primary immunodeficiency when reduced levels of one of more IgG subclasses (with normal total IgG) are accompanied by impaired antibody function (usually demonstrated by abnormal vaccine response). This disorder is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"     \"IgG subclass deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22335714\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunoglobulin G (IgG) can be subdivided into four subclasses: IgG1, IgG2, IgG3, and IgG4. All four subclasses are monomeric and have similar structures. All cross the placenta. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Properties of IgG subclasses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgG subclasses are numbered according to their serum concentrations. IgG1 normally comprises 60 to 70 percent of total IgG, such that low levels of IgG1 usually results in overall hypogammaglobulinemia. (See",
"      <a class=\"local\" href=\"#H3396734\">",
"       'Normal serum concentrations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The class and subclass of an immunoglobulin molecule are determined by the constant heavy chain portion. The amino acid sequences of the various IgG subtypes are 90 to 95 percent homologous, with each subtype having a specific C gene segment that encodes its CH region (eg, gene segment C&gamma;2 encodes the CH regions of IgG2 molecules). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All four IgG subclasses act as opsonins, binding to microbes and facilitating phagocytosis. They have differing abilities to activate the classical complement pathway: IgG1 and IgG3 fix C1q most effectively while IgG2 does so weakly and IgG4 does not bind complement at all. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Biological functions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many antibody responses to pathogens demonstrate &ldquo;IgG subclass restriction,&rdquo; ie, the response is largely composed of certain IgG subtypes: antibody responses to protein antigens and viral antigens are composed predominantly of IgG1 and IgG3, while responses to polysaccharide antigens are mostly IgG2. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Role in specific types of infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The functions of IgG4 remain incompletely defined. It may play a role in the immune response to parasitic infection, but elevations in IgG4 have also been associated with an array of different disorders. (See",
"      <a class=\"local\" href=\"#H3397374\">",
"       'Disorders associated with elevated subclass levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low levels of one or more of the IgG subclasses are found in healthy people, but can also be associated with increased infections and poor vaccine response. The latter is considered to be a form of primary immunodeficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"       \"IgG subclass deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/1\">",
"      Pan Q, Hammarstr&ouml;m L. Molecular basis of IgG subclass deficiency. Immunol Rev 2000; 178:99.",
"     </a>",
"    </li>",
"    <li>",
"     Meulenbroek AJ, Zeijlemaker WP. Human IgG subclasses: Useful diagnostic markers for immunocompetence, 2nd edition, CLB, Amsterdam, The Netherlands 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/3\">",
"      GREY HM, KUNKEL HG. H CHAIN SUBGROUPS OF MYELOMA PROTEINS AND NORMAL 7S GAMMA-GLOBULIN. J Exp Med 1964; 120:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/4\">",
"      TERRY WD, FAHEY JL. SUBCLASSES OF HUMAN GAMMA-2-GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE CHAINS. Science 1964; 146:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/5\">",
"      Burton DR, Gregory L, Jefferis R. Aspects of the molecular structure of IgG subclasses. Monogr Allergy 1986; 19:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/6\">",
"      Jefferis R, Pound J, Lund J, Goodall M. Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article. Ann Biol Clin (Paris) 1994; 52:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/7\">",
"      Pumphrey R. Computer models of the human immunoglobulins. Immunology Today 1986; 7:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/8\">",
"      van der Neut Kolfschoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/9\">",
"      Schuurman J, Van Ree R, Perdok GJ, et al. Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 1999; 97:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/10\">",
"      French M. Serum IgG subclasses in normal adults. Monogr Allergy 1986; 19:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/11\">",
"      Garty BZ, Ludomirsky A, Danon YL, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994; 1:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/12\">",
"      Lee SI, Heiner DC, Wara D. Development of serum IgG subclass levels in children. Monogr Allergy 1986; 19:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/13\">",
"      Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/14\">",
"      Jefferis R, Reimer CB, Skvaril F, et al. Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. Immunol Lett 1985; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/15\">",
"      Hofker MH, Walter MA, Cox DW. Complete physical map of the human immunoglobulin heavy chain constant region gene complex. Proc Natl Acad Sci U S A 1989; 86:5567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/16\">",
"      Lefranc MP, Hammarstr&ouml;m L, Smith CI, Lefranc G. Gene deletions in the human immunoglobulin heavy chain constant region locus: molecular and immunological analysis. Immunodefic Rev 1991; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/17\">",
"      Sarvas H, Rautonen N, M&auml;kel&auml; O. Allotype-associated differences in concentrations of human IgG subclasses. J Clin Immunol 1991; 11:39.",
"     </a>",
"    </li>",
"    <li>",
"     Ochs HD. The B-lymphocyte system: Clinical immunology. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier, Philadelphia 2004. p.89.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/19\">",
"      Steinberg AG. Globulin polymorphisms in man. Annu Rev Genet 1969; 3:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/20\">",
"      Siber GR, Schur PH, Aisenberg AC, et al. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980; 303:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/21\">",
"      Stevens R, Dichek D, Keld B, Heiner D. IgG1 is the predominant subclass of in vivo- and in vitro- produced anti-tetanus toxoid antibodies and also serves as the membrane IgG molecule for delivering inhibitory signals to anti-tetanus toxoid antibody-producing B cells. J Clin Immunol 1983; 3:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/22\">",
"      Spinsanti LI, Far&iacute;as AA, Aguilar JJ, et al. Immunoglobulin G subclasses in antibody responses to St. Louis encephalitis virus infections. Arch Virol 2011; 156:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/23\">",
"      Iskander R, Das PK, Aalberse RC. IgG4 antibodies in Egyptian patients with schistosomiasis. Int Arch Allergy Appl Immunol 1981; 66:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/24\">",
"      Ottesen EA, Skvaril F, Tripathy SP, et al. Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol 1985; 134:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/25\">",
"      Ansari NA, Kumar R, Raj A, Salotra P. Elevated levels of IgG3 and IgG4 subclass in paediatric cases of kala azar. Parasite Immunol 2008; 30:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/26\">",
"      Papadea C, Reimer CB, Check IJ. IgG subclass distribution in patients with multiple myeloma or with monoclonal gammopathy of undetermined significance. Ann Clin Lab Sci 1989; 19:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/27\">",
"      Zhang L, Smyrk TC. Autoimmune pancreatitis and IgG4-related systemic diseases. Int J Clin Exp Pathol 2010; 3:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/28\">",
"      Aalberse RC, Van Milligen F, Tan KY, Stapel SO. Allergen-specific IgG4 in atopic disease. Allergy 1993; 48:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/29\">",
"      Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int 2005; 68:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/30\">",
"      van Nieuwkoop JA, Brand A, Radl J, Skvaril F. Increased levels of IgG4 subclass in 5 patients with acquired respiratory disease. Int Arch Allergy Appl Immunol 1982; 67:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/31\">",
"      Yamamoto M, Takahashi H, Suzuki C, et al. Analysis of serum IgG subclasses in Churg-Strauss syndrome--the meaning of elevated serum levels of IgG4. Intern Med 2010; 49:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/32\">",
"      Tsushima K, Yokoyama T, Kawa S, et al. Elevated IgG4 levels in patients demonstrating sarcoidosis-like radiologic findings. Medicine (Baltimore) 2011; 90:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35078/abstract/33\">",
"      Engelmann R, Brandt J, Eggert M, et al. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatology (Oxford) 2008; 47:1489.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3964 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35078=[""].join("\n");
var outline_f34_16_35078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22335714\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROPERTIES OF IgG SUBCLASSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22335778\">",
"      Structures and physical properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3396734\">",
"      Normal serum concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3397212\">",
"      Half-lives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3396833\">",
"      Allotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BIOLOGICAL FUNCTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2280352\">",
"      Opsonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2280359\">",
"      Complement activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role in specific types of infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3397374\">",
"      DISORDERS ASSOCIATED WITH ELEVATED SUBCLASS LEVELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3397367\">",
"      DISORDERS ASSOCIATED WITH REDUCED SUBCLASS LEVELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22335714\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3964|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/41/21149\" title=\"figure 1\">",
"      Disulfide linkages  in IgG subclasses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/30/19950\" title=\"figure 2\">",
"      IgG structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/0/30734\" title=\"figure 3\">",
"      Normal IgG subclass levels in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3964|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/48/6925\" title=\"table 1\">",
"      Levels of IgG subclasses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=related_link\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13178?source=related_link\">",
"      Overview of IgG4-related disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_16_35079="Foot fractures (other than metatarsal or phalangeal) in children";
var content_f34_16_35079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Foot fractures (other than metatarsal or phalangeal) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35079/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35079/contributors\">",
"     Kathy Boutis, MD, FRCPC, FAAP, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35079/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35079/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35079/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/16/35079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pediatric foot fractures are minor, involve the metatarsal or tarsal bones, and require limited immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1\">",
"     1",
"    </a>",
"    ]. Although rare, talar neck, calcaneal, or tarsometatarsal (Lisfranc) fractures are complex, warrant urgent orthopedic evaluation, and have the potential for long-term complications [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/2\">",
"     2",
"    </a>",
"    ]. This topic will discuss the management of mid- and hindfoot fractures in children. Metatarsal and toe fractures in children and foot fractures in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14903?source=see_link\">",
"     \"Metatarsal and toe fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=see_link\">",
"     \"Metatarsal shaft fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=see_link\">",
"     \"Toe fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28485?source=see_link\">",
"     \"Sesamoid fractures of the foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although forefoot fractures (metatarsal and toe fractures) account for the majority of pediatric foot fractures, midfoot, and hindfoot fractures have the greatest potential for causing permanent deformity and disability.",
"   </p>",
"   <p>",
"    Among these less common foot fractures, talar neck fractures are seen most frequently. Fractures of the calcaneus, cuboid, navicular, cuneiform, or tarsometatarsal (Lisfranc) region are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, as more children and adolescents have become users of motorized recreational vehicles (eg, mini scooters, motorized dirt bikes, all terrain vehicles, snowmobiles) or have participated in snowboarding, the frequency and severity of these foot injuries has increased [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The foot is divided into three regions (",
"    <a class=\"graphic graphic_figure graphicRef78924 graphicRef61079 graphicRef71857 \" href=\"UTD.htm?30/38/31338\">",
"     figure 1A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Forefoot",
"      </strong>",
"      &ndash; Metatarsal and phalangeal bones",
"     </li>",
"     <li>",
"      <strong>",
"       Midfoot",
"      </strong>",
"      &ndash; Navicular, cuboid, and cuneiform bones",
"     </li>",
"     <li>",
"      <strong>",
"       Hindfoot",
"      </strong>",
"      &ndash; Talus and calcaneus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Lisfranc joint separates the forefoot from the midfoot. The Chopart joint divides the hindfoot and the midfoot.",
"   </p>",
"   <p>",
"    The pediatric midfoot and hindfoot differ from the adult foot due to the presence of large portions of growing cartilage in the young child (under four years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1\">",
"     1",
"    </a>",
"    ]. The calcaneus and talus are ossified at birth, and the cuboid ossification center appears at birth or shortly thereafter. The navicular tarsal bone appears around three years of age and is the last of the large tarsal bones to develop a primary ossification center. Thus, a foot radiograph of a child under five years of age lacks significant areas of visible bone. These factors lead to patterns of injuries in young children that may be difficult to identify on plain radiographs and that differ from those in adults.",
"   </p>",
"   <p>",
"    In contrast, the midfoot and hindfoot of adolescents have enough skeletal maturity that they develop fracture patterns that are similar to those seen in adults.",
"   </p>",
"   <p>",
"    The high cartilage to bone ratio in children under age eight years allows for significant remodeling of foot fractures and provides for good long-term outcomes in many instances. However, fractures of the talar neck in children, although rare, may disrupt the vascular supply of the talus and cause avascular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific fractures are associated with certain types of injury patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Talar neck",
"      </strong>",
"      fractures often result from forced dorsiflexion of the foot during a fall or motor vehicle collision [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1,7\">",
"       1,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Fractures of the lateral process of the talus",
"      </strong>",
"      are associated with snowboarding [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/6,8\">",
"       6,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Calcaneus fractures",
"      </strong>",
"      may occur after trivial falls in toddlers and young children. In older children and adolescents, they are associated with falls on to the heel from a significant height (&gt;3 m [10 ft]) or with foot injuries involving motorized vehicles (eg, all terrain vehicles, motorcycles) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cuboid injuries",
"      </strong>",
"      may also result from a fall from a height if the foot hits the ground in a plantar-flexed position, transmitting axial and rotatory forces up along the lateral midfoot and hindfoot. Compression fractures of the cuboid have also occurred in association with horseback riding [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/9\">",
"       9",
"      </a>",
"      ]. In most instances, cuboid fractures are associated with significant fractures to the talus, calcaneus, or tarsometatarsal region [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Tarsometatarsal fractures (Lisfranc fractures)",
"      </strong>",
"      may result from violent plantar flexion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abduction force when falling from a significant height or trying to brake with the foot while riding a motorized vehicle (eg, mini motorized scooter) or bicycle [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3\">",
"       3",
"      </a>",
"      ]. Less commonly, heel to toe compression (eg, a heavy object falling onto the heel with the foot in a kneeling position) may result in similar injuries.",
"     </li>",
"     <li>",
"      <strong>",
"       Osteochondritis dissecans",
"      </strong>",
"      is a condition in which a segment of articular cartilage, with its underlying subchondral bone, gradually separates from the surrounding osteocartilaginous tissue. Osteochondritis dissecans of the talus is described in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=see_link&amp;anchor=H2510199#H2510199\">",
"       \"Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent conditions, such as an open fracture, neurovascular compromise, or compartment syndrome, require prompt recognition and treatment. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Emergency conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the mechanism of injury, the physician's history should ascertain the following [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Site of the most significant pain",
"     </li>",
"     <li>",
"      Other injured areas (eg, lumbar spine, hip, knee)",
"     </li>",
"     <li>",
"      Length of time from injury to presentation",
"     </li>",
"     <li>",
"      Neurovascular symptoms (eg, paresthesias, numbness, foot pallor)",
"     </li>",
"     <li>",
"      Ability to bear weight after injury",
"     </li>",
"     <li>",
"      History of any previous injury or surgery",
"     </li>",
"     <li>",
"      Related orthopedic comorbidities (eg, myelomeningocele, cerebral palsy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A foot fracture, particularly one sustained in a fall from a height, may mask other injuries, especially spinal column compression fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete evaluation of the entire lower extremity should be conducted before assuming that the injury is confined to the foot, especially in a child who is less than five years of age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    is nonverbal [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1\">",
"     1",
"    </a>",
"    ]. Most children with foot fractures have significant pain or are unwilling to bear weight on the affected side.",
"   </p>",
"   <p>",
"    After a foot injury, there is often swelling and pain. Patients who have sustained major trauma (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 2",
"    </a>",
"    ) are at risk for multiple traumatic injuries and warrant a complete physical examination and appropriate ancillary studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\", section on 'Approach to blunt trauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H8#H8\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once other injuries are excluded, the examination can focus on the ankle. Analgesia prior to examination (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum dose 800 mg for mild pain or intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum single dose: 10 mg for moderate or severe pain) will often facilitate the child's cooperation. We suggest that the clinician avoid the oral route for patients likely to require sedation or general anesthesia for fracture reduction or repair.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inspection",
"      </strong>",
"      &ndash; Clinicians should inspect the injured foot for:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Swelling",
"     </li>",
"     <li>",
"      Deformity",
"     </li>",
"     <li>",
"      Skin abnormalities (eg, lacerations (possible open fracture), tenting, or blistering (caused by rapid stretching of the skin))",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Palpation",
"      </strong>",
"      &ndash; Palpation should include all of the bones of the lower leg, ankle, and foot. Patterns of pain and swelling assist in identifying the site of foot fracture:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Talar fractures",
"      </strong>",
"      &ndash; Pain and swelling of the ankle and tenderness just distal to the anterior ankle joint are present. Nondisplaced talar fractures may lack significant tenderness but should be suspected in patients who have pain on ambulation after a high force dorsiflexion injury.",
"     </li>",
"     <li>",
"      <strong>",
"       Calcaneal fractures",
"      </strong>",
"      &ndash; Careful examination of the heel of the foot is warranted in any child refusing to walk after a fall. Associated soft tissue or other skeletal injuries (eg, compression fracture of the lumbar spine, tibial plateau fracture) are present in half of the children with calcaneal fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cuboid fractures",
"      </strong>",
"      &ndash; These injuries present with tenderness in the lateral (outer) aspect of the midfoot.",
"     </li>",
"     <li>",
"      <strong>",
"       Navicular fracture",
"      </strong>",
"      &ndash; Pain on the medial (inner) aspect of the midfoot is typical for these fractures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tarsometatarsal (Lisfranc) fractures",
"      </strong>",
"      &ndash; Pain and tenderness in the midfoot region and dorsal or plantar ecchymosis are typically present (",
"      <a class=\"graphic graphic_picture graphicRef64675 \" href=\"UTD.htm?30/20/31040\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/10\">",
"       10",
"      </a>",
"      ]. Pronation-abduction stress may elicit midfoot pain [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Compartment syndrome",
"      </strong>",
"      &ndash; Compartment syndrome presents with marked tense swelling of the foot and pain out of proportion to the degree of injury. Pallor, paresthesias, and pulselessness are late signs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs, with anterior-posterior (AP), lateral, and oblique views of the foot, remain the most appropriate initial imaging modality and suffice for most low energy foot injuries in children. In rare instances, comparison views with the uninjured foot may be helpful in identifying subtle fractures. Additional views should be based on clinical findings that suggest the area of fracture (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical presentation and examination'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Talus",
"      </strong>",
"      &ndash; Fractures of the talus include fractures of the neck, body, medial or lateral process, and osteochondral injuries. Among these, talar neck fractures are most common and are described using the Hawkins classification system (",
"      <a class=\"graphic graphic_figure graphicRef53096 \" href=\"UTD.htm?14/17/14613\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65869 \" href=\"UTD.htm?25/27/26034\">",
"       image 1",
"      </a>",
"      ). Computed tomography should be included in the radiographic series in a patient with significant lateral foot pain with negative plain radiographs, since fractures of the lateral process of the talus are sometimes occult and x-rays are negative in over 40 percent of cases.",
"     </li>",
"     <li>",
"      <strong>",
"       Calcaneus",
"      </strong>",
"      &ndash; Axial views of the foot should be added to the standard series in patients with suspected calcaneus fractures. However, a low threshold for computed tomography should be maintained since up to 50 percent of pediatric calcaneal fractures are initially missed (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66449 \" href=\"UTD.htm?41/15/42224\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77701 \" href=\"UTD.htm?8/42/8864\">",
"       image 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/11\">",
"       11",
"      </a>",
"      ]. Most calcaneus fractures in children heal uneventfully; although fractures with significant intraarticular involvement and displacement can yield poorer results (",
"      <a class=\"graphic graphic_figure graphicRef65868 \" href=\"UTD.htm?6/41/6808\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Computed tomography'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Midfoot fractures",
"      </strong>",
"      &ndash; Most isolated midfoot fractures affect the cuboid (outer aspect of the midfoot) or navicular bones (inner aspect of the midfoot) and consist of minor avulsion or stress fractures. Initial plain radiographs may be normal in children with stress fractures. Repeat films in one to two weeks usually show a sclerotic line of healing. Bone scan will not change the clinical management despite a positive study and is almost never ordered.",
"      <br/>",
"      <br/>",
"      Complete fractures of the midfoot typically occur after high force complex foot injuries and are associated with other fractures, especially tarsometatarsal (Lisfranc) fractures. Compression fracture of the cuboid (\"nutcracker\" fracture) is associated with horseback riding.",
"      <br/>",
"      <br/>",
"      K&ouml;hler disease, an apophysitis of the tarsal navicular, is an uncommon cause of limp in children between the ages of two and nine years (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64819 \" href=\"UTD.htm?6/55/7024\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link&amp;anchor=H26#H26\">",
"       \"Overview of the causes of limp in children\", section on 'K&ouml;hler disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tarsometatarsal (Lisfranc) fracture",
"      </strong>",
"      &ndash; Children with a suspected tarsometatarsal (Lisfranc) injury based on clinical presentation or radiographs should undergo computed tomography. The most common pediatric injury consists of medial dislocation (first metatarsal displaced from first cuneiform bone) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52617 \" href=\"UTD.htm?35/0/35845\">",
"       image 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talar fractures, intraarticular calcaneus fractures, and tarsometatarsal",
"    <span class=\"nowrap\">",
"     fractures/dislocations",
"    </span>",
"    are the most common indications for computed tomography (CT) of the foot (",
"    <a class=\"graphic graphic_figure graphicRef54662 \" href=\"UTD.htm?22/12/22725\">",
"     figure 5",
"    </a>",
"    ). With these fractures, CT can provide the primary diagnosis for initial management in the emergency department and provides key information if the need for later operative repair is anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) of foot injuries is rarely performed as part of the acute evaluation because the information typically does not change initial management. MRI may be useful in children whose radiographic imaging remains normal but whose recovery from injury is prolonged and is especially helpful in detecting osteochondral abnormalities in young children. MRI can also be used to monitor vascularity in children with talar neck fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Emergency conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should obtain emergent orthopedic consultation in the patients with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Open fractures",
"      </strong>",
"      &ndash; These injuries usually involve a motor vehicle collision or are machine-related, often involving a lawn mower, chainsaw, or heavy weight [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/1\">",
"       1",
"      </a>",
"      ]. Patients with open fractures should be managed in accordance with the principles of advanced trauma life support (ATLS), including a thorough examination of the entire lower extremity (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Open fractures are frequently grossly contaminated wounds and should be treated with empiric parenteral antibiotics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"       cefazolin",
"      </a>",
"      25",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose 1 gram) and thorough operative irrigation and debridement. In addition, tetanus prophylaxis should be provided, as needed (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H17#H17\">",
"       \"Minor wound preparation and irrigation\", section on 'Irrigation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Compartment syndrome",
"      </strong>",
"      &ndash; Compartment syndrome presents with marked swelling and pain out of proportion to the degree of injury. Pallor, paresthesias, and pulselessness are late signs. Emergent orthopedic consultation is indicated. Once the clinician suspects an acute compartment syndrome, compartment pressures must be measured to determine whether they are elevated, or a clinical decision to perform a fasciotomy is needed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"       \"Acute compartment syndrome of the extremities\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Vascular compromise",
"      </strong>",
"      &ndash; Vascular compromise following foot fractures most commonly occurs due to compartment syndrome as direct vascular insufficiency due to a displaced fracture is rare in this region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Analgesia and initial care",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with no signs of neurovascular compromise, initial therapy consists of measures to reduce swelling and pain management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The affected foot should be elevated above the level of the heart. An insulated ice pack should be applied to help manage swelling.",
"     </li>",
"     <li>",
"      Oral analgesia (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose 800 mg) may suffice for patients with mild pain after a foot injury. Parenteral analgesia (eg, intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      0.1 to 0.15",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose: 10 mg) is most appropriate for initial pain control in patients with moderate to severe pain and should be given prior to radiographic evaluation. We suggest that the clinician avoid the oral route for patients likely to require sedation or general anesthesia for fracture reduction or repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following injuries warrant urgent orthopedic consultation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fractures with vascular compromise or suspected compartment syndrome",
"     </li>",
"     <li>",
"      Any talar neck fracture",
"     </li>",
"     <li>",
"      Intraarticular calcaneus fractures",
"     </li>",
"     <li>",
"      Tarsometatarsal fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DEFINITIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of pediatric foot fractures is guided by small case series and empirical observation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Talar fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any talar neck fracture should be reviewed by an orthopedist. Due to the risk of avascular necrosis, it is important to have a coordinated approach to acute treatment and close follow-up. However, a minimally displaced talar neck fracture (&lt;5 mm) or lateral process of the talus fracture is typically immobilized using a short leg posterior splint or short leg cast with orthopedic follow-up in five to seven days. Subsequently, these fractures are treated in a long leg plaster cast for six to eight weeks. Fewer than 5 mm of displacement and fewer than five degrees of malalignment on anterior-posterior (AP) view are acceptable because the talus has good remodeling potential in children [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nondisplaced lateral process talus fractures are treated with immobilization and non-weight bearing for four to six weeks.",
"   </p>",
"   <p>",
"    Displaced talar neck or lateral process fractures typically require open reduction and internal fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3,6,8,13\">",
"     3,6,8,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Calcaneal fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of these fractures are extraarticular (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66449 \" href=\"UTD.htm?41/15/42224\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77701 \" href=\"UTD.htm?8/42/8864\">",
"     image 3",
"    </a>",
"    ) and usually heal well with immobilization alone [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/4\">",
"     4",
"    </a>",
"    ]. These fractures may be immobilized with a posterior short leg splint or short leg cast. Orthopedic follow-up should occur within seven days.",
"   </p>",
"   <p>",
"    Satisfactory results are seen even in fractures with some depression of the posterior facet (",
"    <a class=\"graphic graphic_figure graphicRef65868 \" href=\"UTD.htm?6/41/6808\">",
"     figure 4",
"    </a>",
"    ) because of good remodeling potential [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/11\">",
"     11",
"    </a>",
"    ]. Nondisplaced or minimally displaced fractures are immobilized in a non-weight bearing short leg cast for five to six weeks to allow healing.",
"   </p>",
"   <p>",
"    Intraarticular fractures warrant urgent orthopedic consultation. Operative reduction and stabilization is required in children with severe displacement or joint depression [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/4\">",
"     4",
"    </a>",
"    ]. Compartment syndrome is of significant concern in children with these fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Midfoot fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with avulsion fractures of the navicular or cuboid bones may be immobilized with a posterior short leg splint or short leg cast with orthopedic referral in seven days. Definitive treatment consists of a walking cast for three to four weeks.",
"   </p>",
"   <p>",
"    For a displaced fracture with articular incongruity, urgent orthopedic surgical consultation is indicated. For compression or \"nutcracker\" fractures of the cuboid, surgical treatment with bone grafting may be necessary to prevent long-term pain and disability [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tarsometatarsal (Lisfranc) fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nondisplaced or minimally displaced (&lt;2 to 3 mm) fractures may undergo posterior short leg splinting or short leg casting with orthopedic follow-up in seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/10\">",
"     10",
"    </a>",
"    ]. Definitive care consists of a short leg cast for three to four weeks. The position should be monitored by frequent follow-up radiographs.",
"   </p>",
"   <p>",
"    Displaced injuries warrant prompt orthopedic consultation for operative reduction and stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term complications following hindfoot and midfoot fractures are less common in children than adults. The location of the injury strongly determines the likelihood of complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avascular necrosis of the body of the talus is a serious complication of talar neck fractures that may develop weeks to months after injury. Displaced fractures are at highest risk [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3\">",
"       3",
"      </a>",
"      ]. Ongoing orthopedic follow-up is typically necessary for one to two years after injury.",
"     </li>",
"     <li>",
"      Calcaneal fractures which remain extraarticular or cause mild joint depression typically have good clinical outcomes in children with few complications [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/5,15\">",
"       5,15",
"      </a>",
"      ]. However, displaced intraarticular injuries may result in long-term joint pain or stiffness.",
"     </li>",
"     <li>",
"      Compression fractures of the cuboid (\"nutcracker\" fracture) may lead to alterations in foot mechanics and severe pain [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/9,14\">",
"       9,14",
"      </a>",
"      ]. Other midfoot injuries heal well in children.",
"     </li>",
"     <li>",
"      Tarsometatarsal (Lisfranc) fractures run a more benign course in children than in adults. Acute associated complications include forefoot ischemia and skin necrosis. Late degenerative changes with pain and loss of function are also possible [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35079/abstract/3,16\">",
"       3,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although forefoot fractures (metatarsal and toe fractures) account for the majority of pediatric foot fractures, midfoot and hindfoot fractures have the greatest potential for causing permanent deformity and disability. In the group of midfoot and hindfoot fractures, talar neck fractures are seen most frequently. Fractures of the calcaneus, cuboid, navicular, cuneiform, or tarsometatarsal (Lisfranc) region are rare. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Relevant anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical findings and imaging",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with fractures of the midfoot and hindfoot are unable to walk or have marked limitation of ambulation. The child with a hindfoot or midfoot fracture typically has a history of significant foot trauma with swelling and pain over the fracture site. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent conditions, such as an open fracture, neurovascular compromise, or compartment syndrome require prompt recognition and treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Emergency conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs, with anterior-posterior (AP), lateral, and oblique views of the foot, remain the most appropriate initial imaging modality and suffice for most low energy injuries. In rare instances, comparison views with the uninjured foot may be helpful in identifying subtle fractures. An axial view is indicated for children with a suspected calcaneus fracture. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Talar fractures, calcaneus fractures, and tarsometatarsal",
"      <span class=\"nowrap\">",
"       fractures/dislocations",
"      </span>",
"      are the most common indications for computed tomography (CT) of the foot. With these fractures, CT can provide the initial diagnosis and information for possible later operative repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician should obtain emergent orthopedic consultation in patients with vascular compromise, compartment syndrome, or open fractures of the metatarsal bone or proximal phalanx. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Emergency conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with no signs of neurovascular compromise, initial therapy consists of analgesia and measures to reduce swelling and pain. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Analgesia and initial care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should obtain urgent orthopedic consultation, generally within one to two days, for children with any of the following foot fractures (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Any talar neck fracture",
"     </li>",
"     <li>",
"      Intraarticular calcaneus fractures",
"     </li>",
"     <li>",
"      Tarsometatarsal fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nondisplaced foot fractures may be treated with a posterior short leg splint or a short leg cast. These patients should be evaluated by an orthopedist with pediatric expertise within one week. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Definitive treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Displaced foot fractures warrant urgent orthopedic consultation for possible operative reduction and fixation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Definitive treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jarvis, JG, Moroz, PJ. Fractures and dislocations of the foot. In: Fractures in Children, 6th, Beaty, JH, Kasser, JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/2\">",
"      Mayr J, Peicha G, Grechenig W, et al. Fractures and dislocations of the foot in children. Clin Podiatr Med Surg 2006; 23:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/3\">",
"      Ribbans WJ, Natarajan R, Alavala S. Pediatric foot fractures. Clin Orthop Relat Res 2005; :107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/4\">",
"      Schneidmueller D, Dietz HG, Kraus R, Marzi I. [Calcaneal fractures in childhood: a retrospective survey and literature review]. Unfallchirurg 2007; 110:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/5\">",
"      Petit CJ, Lee BM, Kasser JR, Kocher MS. Operative treatment of intraarticular calcaneal fractures in the pediatric population. J Pediatr Orthop 2007; 27:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/6\">",
"      Chan GM, Yoshida D. Fracture of the lateral process of the talus associated with snowboarding. Ann Emerg Med 2003; 41:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/7\">",
"      Hawkins LG. Fractures of the neck of the talus. J Bone Joint Surg Am 1970; 52:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/8\">",
"      Leibner ED, Simanovsky N, Abu-Sneinah K, et al. Fractures of the lateral process of the talus in children. J Pediatr Orthop B 2001; 10:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/9\">",
"      Ceroni D, De Rosa V, De Coulon G, Kaelin A. Cuboid nutcracker fracture due to horseback riding in children: case series and review of the literature. J Pediatr Orthop 2007; 27:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/10\">",
"      Benirschke SK, Meinberg E, Anderson SA, et al. Fractures and dislocations of the midfoot: Lisfranc and Chopart injuries. J Bone Joint Surg Am 2012; 94:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/11\">",
"      Inokuchi S, Usami N, Hiraishi E, Hashimoto T. Calcaneal fractures in children. J Pediatr Orthop 1998; 18:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/12\">",
"      Robert IE, Hyde CJ, Bridgman SA. Orthopaedic fractures: trends in randomised controlled trials. Injury 2001; 32:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/13\">",
"      Letts RM, Gibeault D. Fractures of the neck of the talus in children. Foot Ankle 1980; 1:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/14\">",
"      Holbein O, Bauer G, Kinzl L. Fracture of the cuboid in children: case report and review of the literature. J Pediatr Orthop 1998; 18:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/15\">",
"      Mora S, Thordarson DB, Zionts LE, Reynolds RA. Pediatric calcaneal fractures. Foot Ankle Int 2001; 22:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35079/abstract/16\">",
"      Buoncristiani AM, Manos RE, Mills WJ. Plantar-flexion tarsometatarsal joint injuries in children. J Pediatr Orthop 2001; 21:324.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6555 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35079=[""].join("\n");
var outline_f34_16_35079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RADIOGRAPHIC DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Emergency conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Analgesia and initial care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DEFINITIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Talar fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Calcaneal fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Midfoot fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tarsometatarsal (Lisfranc) fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical findings and imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6555\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6555|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/27/26034\" title=\"diagnostic image 1\">",
"      Talar neck fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/15/42224\" title=\"diagnostic image 2\">",
"      Calcaneus fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/42/8864\" title=\"diagnostic image 3\">",
"      Calcaneus avulsion fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/55/7024\" title=\"diagnostic image 4\">",
"      Kohler disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/0/35845\" title=\"diagnostic image 5\">",
"      Tarsometatarsal fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6555|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/7/30835\" title=\"figure 1A\">",
"      Foot anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38530\" title=\"figure 1B\">",
"      Foot anatomy medial view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/20/2375\" title=\"figure 1C\">",
"      Foot anatomy superior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 2\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/17/14613\" title=\"figure 3\">",
"      Talar fracture classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/41/6808\" title=\"figure 4\">",
"      Calcaneus anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/12/22725\" title=\"figure 5\">",
"      Calcaneus CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6555|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/20/31040\" title=\"picture 1\">",
"      Plantar ecchymosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6555|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=related_link\">",
"      Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14903?source=related_link\">",
"      Metatarsal and toe fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=related_link\">",
"      Metatarsal shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=related_link\">",
"      Overview of the causes of limp in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28485?source=related_link\">",
"      Sesamoid fractures of the foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=related_link\">",
"      Toe fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_16_35080="Mantle cell lymphoma Light";
var content_f34_16_35080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mantle cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a mantle cell lymphoma shows diffuse proliferation of small to medium-sized lymphoid cells with slight nuclear irregularity. A residual naked germinal center is seen in the upper left-hand corner (400x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy, III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35080=[""].join("\n");
var outline_f34_16_35080=null;
var title_f34_16_35081="Pathogenesis of the antiphospholipid syndrome";
var content_f34_16_35081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of the antiphospholipid syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35081/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35081/contributors\">",
"     Bonnie L Bermas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35081/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35081/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35081/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/16/35081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid antibody syndrome (APS) is defined by the presence of two major components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence in the plasma of at least one type of autoantibody known as an antiphospholipid antibody (aPL).",
"     </li>",
"     <li>",
"      The occurrence of at least one of the following clinical manifestations: venous or arterial thromboses, or pregnancy morbidity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the clinical manifestations of APS occur in other disease populations, in the APS they occur by definition in the context of aPL. aPL, which are directed against plasma proteins bound to anionic phospholipids, may be detected as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lupus anticoagulants",
"     </li>",
"     <li>",
"      Anticardiolipin antibodies",
"     </li>",
"     <li>",
"      Antibodies to &szlig;2 glycoprotein-I",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The full clinical significance of other autoantibodies, including those directed against prothrombin, annexin V, phosphatidylserine, and phosphatidylinositol, remain unclear.",
"   </p>",
"   <p>",
"    APS occurs either as a primary condition or in the setting of an underlying disease, particularly systemic lupus erythematosus (SLE).",
"   </p>",
"   <p>",
"    The pathogenesis of the APS will be reviewed here. The clinical manifestations, diagnosis, and treatment of the APS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIPHOSPHOLIPID ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The APS is characterized by antibodies directed against epitopes on plasma proteins that are uncovered or generated by the binding of these proteins to phospholipids; they do not bind directly to anionic phospholipids [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The mechanisms by which aPL cause thrombosis are not completely understood.",
"   </p>",
"   <p>",
"    There are a variety of tests that can detect aPL:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticardiolipin antibodies",
"     </li>",
"     <li>",
"      Functional assays for the detection of aPL with lupus anticoagulant activity",
"     </li>",
"     <li>",
"      Anti-&szlig;2-glycoprotein-I antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tests vary in their sensitivity and specificity.",
"   </p>",
"   <p>",
"    The standard types of aPL assays performed are enzyme-linked immunoassays (ELISAs) for anticardiolipin antibodies (aCL) and antibodies to &szlig;2-glycoprotein-I (&szlig;2-GP-I), and coagulation tests designed to detect lupus anticoagulants (LAs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anticardiolipin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;aCL react with cardiolipin but may also react with phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, &szlig;2-GP-I, prothrombin, or annexin V [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concordance between the presence of an LA and aCL is approximately 85 percent. In many cases, however, LAs comprises a separate population of antibodies from aCL [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. Thus, testing should be performed for both LAs and aCL if APS is suspected on a clinical basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated levels of IgG aCL confer a greater risk of thrombosis than do other immunoglobulin isotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/6\">",
"     6",
"    </a>",
"    ]. However, IgM and IgA aCL isotypes may be associated with the APS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     False positive serologic test for syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biologic false positive test for syphilis (BFPTS) phenomenon occurs because the syphilis antigen used in the VDRL and RPR tests is cardiolipin mixed with cephaline and cholesterol. Examples of BFPTS are positive rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) tests that are not confirmed by specific treponemal assays. These tests for the diagnosis of syphilis have been replaced by specific antitreponemal tests in most laboratories.",
"   </p>",
"   <p>",
"    RPR and VDRL assays, if available, are not appropriate screening tests for aPL because of their low sensitivities and specificities [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnostic testing for syphilis\", section on 'Interpretation of serologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lupus anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAs are antibodies directed against plasma proteins such as &szlig;2-GP-I, prothrombin, or annexin V that are bound to anionic phospholipids [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. The phrase \"the lupus anticoagulant\" is a misnomer, for three reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of an LA is generally associated with a clotting tendency, not an anticoagulant effect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Thrombosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      More than one antibody is associated with LA activity. As examples, both aCL and antibodies to &szlig;2-GP-I can have LA activity.",
"     </li>",
"     <li>",
"      Only about 50 percent of individuals with an LA meet the American College of Rheumatology criteria for the classification of SLE. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H38#H38\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Primary APS versus APS with SLE'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because there is more than one LA and not all antibodies with APS are associated with anticoagulant activity, the detection of LAs occurs through functional clotting tests, not through enzyme-linked immunosorbent assays (ELISAs). LAs block in vitro assembly of the prothrombinase complex, resulting in a prolongation of in vitro clotting assays such as the activated partial thromboplastin time (aPTT), the dilute Russell viper venom time (dRVVT), the kaolin clotting time and, infrequently, the prothrombin time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of the antiphospholipid syndrome\", section on 'Lupus anticoagulant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Prolongation of clotting times",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clotting factor deficiencies that lead to prolongation of coagulation assays are reversed when the patient's plasma is diluted 1:1 with normal platelet-free plasma. Such a procedure is known as a mixing study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical use of coagulation tests\", section on 'Mixing studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, abnormalities of coagulation assays are not reversed when the cause is an LA [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. However, they can be reversed by incubation of the patient's plasma with a hexagonal phase phospholipid that neutralizes the inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/1,4,9\">",
"     1,4,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Abnormal bleeding times",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with LAs have prolonged bleeding times despite adequate platelet counts [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Although these changes suggest impaired coagulation, patients with an LA have a paradoxical increase in the frequency of arterial and venous thrombotic events [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anti-&szlig;2-glycoprotein-I antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;&szlig;2-GP-I (apolipoprotein H) is a naturally occurring inhibitor of coagulation and platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/17\">",
"     17",
"    </a>",
"    ]. The properties of this protein as a clotting inhibitor could explain why neutralizing antibodies promote thrombosis. Consistent with this hypothesis is the observation that aPL prolong the aPTT if added to normal plasma but not to plasma depleted of &szlig;2-GP-I [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/18\">",
"     18",
"    </a>",
"    ]. &szlig;2-GP-I binds to negatively-charged phospholipids such as phosphatidylserine and phosphatidylinositol and inhibits both contact activation of the clotting cascade and the conversion of prothrombin to thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies to &szlig;2-GP-I are found in a large percentage of patients with primary or secondary APS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/21\">",
"     21",
"    </a>",
"    ]. Although antibodies to &szlig;2-GP-I are usually found in association with other aPL, they are the sole aPL detectable in approximately 11 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Additional aPL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to aCL, LAs, and antibodies to &szlig;2-GP-I, other antibodies have been reported in association with clinical features of the APS. These include antibodies to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prothrombin",
"     </li>",
"     <li>",
"      Annexin V",
"     </li>",
"     <li>",
"      Phosphatidylserine",
"     </li>",
"     <li>",
"      Phosphatidylinositol",
"     </li>",
"     <li>",
"      Phosphatidylethanolamine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, assays for these antibodies are not standardized for clinical use. Their interpretation and relevance to clinical practice remains unclear. Among these additional aPL, the largest amount of literature relates to antiprothrombin antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antiprothrombin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiprothrombin antibodies have been described in association with both clotting and hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/22\">",
"     22",
"    </a>",
"    ]. The presence of prothrombin antibodies should be suspected when a patient with known aPL develops a bleeding tendency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H19#H19\">",
"     \"Acquired inhibitors of coagulation\", section on 'Other coagulation factor inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiprothrombin antibodies have been described in 50 percent of patients with aPL, 34 percent of patients with SLE, and 57 percent of patients with Sneddon's syndrome (livedo reticularis with stroke or transient ischemic attacks) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies directed against prothrombin may interfere with coagulation in conjunction with other aPL [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example, antibodies to a complex of phosphatidylserine and prothrombin appear to be more significant in terms of the risk of clinical events than antibodies to prothrombin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H20#H20\">",
"     \"Acquired inhibitors of coagulation\", section on 'Prothrombin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiprothrombin antibodies are also associated with an increased likelihood of recurrent venous thromboembolic disease that is independent of the presence of aCL or LA. In one study of 236 consecutive patients with acute venous thrombotic events, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      aPL were found in 85 (36 percent), of whom 24 (10 percent of the overall cohort) had antiprothrombin antibodies.",
"     </li>",
"     <li>",
"      A history of previous thromboembolism was identified in nearly one-quarter of the patients. In a multivariate analysis, antiprothrombin antibodies were associated with previous thromboembolism (odds ratio 3.3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Future studies and further refinement of APS assays are likely to clarify the role of antibodies to prothrombin, annexin V, phosphatidylserine, and other aPL targets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the APS associated clinical manifestations appears to result from a variety of aPL effects upon pathways of coagulation, including the procoagulant actions of these antibodies upon protein C, annexin V, platelets, serum proteases, toll-like receptors, tissue factor, and via impaired fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/29-36\">",
"     29-36",
"    </a>",
"    ]. In addition to heightening the risk of vascular thrombosis, aPL increase vascular tone, thereby increasing the susceptibility to atherosclerosis, fetal loss, and neurological damage [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly accepted explanation for the development of aPL is that they occur in susceptible individuals following incidental exposure to infectious agents. However, aside from the milieu of rheumatic diseases such as SLE, the conditions creating such susceptibility remain largely undefined.",
"   </p>",
"   <p>",
"    Current thinking about the pathogenesis of the APS holds that once aPL are present, a \"second-hit\" is required for the development of the full-blown syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/38\">",
"     38",
"    </a>",
"    ]. Potential candidates for the delivery of such a second hit are smoking, prolonged immobilization, pregnancy and the post-partum period, oral contraceptive use, hormone replacement therapy, malignancy, nephrotic syndrome, hypertension, and hyperlipidemia.",
"   </p>",
"   <p>",
"    Clues to the pathogenesis of the APS derive from in vitro experiments, animal models, and clinical studies in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     In vitro experiments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple in vitro experiments suggest that antibodies to &szlig;2-GP-I play an important role in the thrombotic events associated with APS. The range of findings is summarized by the following points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &szlig;2-GP-I helps maintain adequate plasma levels of free protein S [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/39\">",
"       39",
"      </a>",
"      ]. Antibodies to &szlig;2-GP-I may cause thrombosis by interfering with the activity of protein S. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link&amp;anchor=H2#H2\">",
"       \"Protein S deficiency\", section on 'Physiology of protein S'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other aPL may have similar effects on protein C and other coagulation factors through binding to these proteins or receptors on endothelial cell surfaces [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/40-43\">",
"       40-43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H2#H2\">",
"       \"Protein C deficiency\", section on 'Physiology of protein C'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Specific T cells in APS patients respond to stimulation with &szlig;2-GP-I [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/44\">",
"       44",
"      </a>",
"      ]. Depletion of these T cells significantly reduces anti-&szlig;2-GP-I antibody production.",
"     </li>",
"     <li>",
"      Complexes of &szlig;2-GP-I and aCL bind to platelet phospholipids, upregulating coagulation and stimulating platelet aggregation [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/45\">",
"       45",
"      </a>",
"      ]. Antibody binding to &szlig;2-GP-I attached to the platelet glycoprotein Ib-IX-V receptor may lead to platelet activation [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to &szlig;2-GP-I may cross-react with antigenic determinants on endothelial cell CD40 [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/47\">",
"       47",
"      </a>",
"      ]. CD40 ligation in vitro causes endothelial cell activation characterized in part by increased surface expression of adhesion molecules [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      APL may lead to platelet activation and facilitate the adherence of platelets to endothelium [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/40,49\">",
"       40,49",
"      </a>",
"      ]. This effect may be enhanced by the presence of antibodies to both aCL, &szlig;2-GP-I, and",
"      <span class=\"nowrap\">",
"       phosphatidylserine/prothrombin",
"      </span>",
"      complexes [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/50\">",
"       50",
"      </a>",
"      ], as well as by the presence of thrombin [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      APL may activate vascular endothelium, resulting in increased binding of monocytes and activated platelets and the expression of tissue factor, chemokines, and growth factors [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/52-55\">",
"       52-55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following data from animal models that are relevant to the pathogenesis of the APS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Findings in a mouse model of APS challenge the dogma that this syndrome is entirely a noninflammatory, thrombotic disease, and provide evidence that complement activation is critical for APS pregnancy complications [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the same mouse model, aPL-induced fetal loss may be inhibited by treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/58\">",
"       58",
"      </a>",
"      ], and some evidence in humans suggests that similar findings apply to patients with the APS [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical studies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The infusion of human or murine aCL or immunization with a monoclonal human aCL prolongs the PTT and increases the rate of fetal loss in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from a mouse model suggest that antibodies directed against an antigenic hexapeptide derived from &szlig;2-GP-I may cross-react with bacterial proteins containing the same motif (ie, possible molecular mimicry) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/62\">",
"       62",
"      </a>",
"      ]. Passive transfer of purified antibodies to the hexapeptide was associated with decreased platelets counts, fetal resorption, and prolongation of the activated partial tissue thromboplastin time.",
"     </li>",
"     <li>",
"      In other mouse experiments, antibodies to a 15 amino acid peptide derived from &szlig;2-GP-I transfer disease [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/63\">",
"       63",
"      </a>",
"      ]. Some data indicate that one &szlig;2-GP-I domain (domain I) plays a role in human disease [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies in humans are consistent with findings from in vitro and animal model experiments about the importance of complement activation and antibodies to &szlig;2-GP-I in disease pathogenesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with primary APS had lower levels of CH50, C3 and C4 than controls; they also had increased levels of complement fragments indicative of complement activation (ie, C3a and C4a) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When immunohistochemical analyses were performed on placentas from 47 patients with aPL and 23 healthy controls, there was evidence of increased complement deposition within the trophoblast cytoplasm, trophoblastic cell and basement membrane, and extravillous trophoblasts of placentas from aPL patients [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/59\">",
"       59",
"      </a>",
"      ]. These findings are consistent with murine studies implicating complement as a critical factor in fetal tissue injury [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/56-58\">",
"       56-58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it remains uncertain whether complement activation causes a hypercoagulable state, or, results from it.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies to &szlig;2-GP-I correlate better with the development of APS than do aCL or LAs alone [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/1,66-70\">",
"       1,66-70",
"      </a>",
"      ]. As an example, in a study of 100 patients with an LA, 12 of the 14 who developed a thromboembolic event had prolongations of their dilute Russell viper venom time (dRVVT) assay, a coagulation test that is highly sensitive for antibodies to &szlig;2-GP-I [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to &szlig;2-GP-I were found in 35 of 39 lupus patients with features of APS compared with only two of 55 patients without APS [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. As noted above, patients with syphilis and other infections that often lead to aCL production do not form anti-&szlig;2-GP-I antibodies, which may explain why they do not become hypercoagulable [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/40,66,67\">",
"       40,66,67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with antibodies to &szlig;2-GP-I but without either LA or aCL can display the clinical features of APS, including venous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arterial thromboses [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/21,71\">",
"       21,71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      APS patients express greater quantities of tissue factor, the major initiator of coagulation in vivo, on the surfaces of monocytes. In one report, enhanced monocyte expression of tissue factor was observed in patients with primary APS and a history of thrombosis, but not in patients with aPL without thrombosis or in patients with thrombosis but without aPL [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/72\">",
"       72",
"      </a>",
"      ]. Monocytes from patients with thromboembolic phenomena also appear to over-express potentially procoagulant proteins including: annexin I and II, protein disulfide isomerase, Nedd8, RhoA, and heat shock protein-60 on their surfaces; in contrast, monocytes from patients with recurrent abortions reportedly over-express fibrinogen and hemoglobin [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Interaction with other antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;APL may also exert their effects through complex interactions with other antibodies. As examples, patients with aPL may also have antibodies directed against",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"     /heparan",
"    </span>",
"    sulfate, platelet-activating factor, tissue-type plasminogen activator, annexins (2, IV, and V), thromboplastin, oxidized low density lipoproteins, thrombomodulin, kininogen, and coagulation factors VII, VIIa, and XII [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/23,24,37,74-87\">",
"     23,24,37,74-87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Microparticles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microparticles are fragments of cell surface membranes that are released from apoptotic, activated, and damaged cells. The plasma concentration of microparticles that are derived from endothelial cells is increased among patients with APS when compared to people with aPL without thrombotic events and to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link&amp;anchor=H9#H9\">",
"     \"Endothelial dysfunction\", section on 'Microparticles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     GENETIC PREDISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although genetic studies of the APS are in their infancy, genetic risk factors such as concurrence of coagulation factor mutations heighten the risk of aPL-associated thrombosis. In different studies, factor V Leiden and the prothrombin gene mutation and activated protein C resistance were associated with an increased risk of venous thromboembolism in patients with aPL [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. (See appropriate topic reviews on the different hypercoagulable states).",
"   </p>",
"   <p>",
"    Several other types of studies have implicated genetic factors in the pathogenesis of the APS. The following are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relatives of probands with aPL are more likely to have aPL. In a series of 23 patients with aCL, for example, 29 of their 87 relatives (33 percent) also had aCL [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a strong association of aPL with HLA-DR7 in Canadian, German, Italian, and Mexican patients, and with HLA-DQ7 in American and Spanish patients [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The expression of various aPL was associated with HLA-DRB1*04 and HLA&ndash;DRB1*13 in a large Swedish cohort of patients with SLE; these alleles were also more frequent among patients with ischemic cerebrovascular disease (ICVD) and with any vascular event (ICVD, ischemic heart disease, and venous thromboembolism combined), respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Weaker associations have been noted between APS and various polymorphisms of the immunoglobulin receptor (Fcgamma RIIA) and platelet glycoproteins [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/96,97\">",
"       96,97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The inheritance of certain polymorphisms of the &szlig;2-GP-I gene and of the HLA-DMA and HLA-DMB genes may also enhance the risk of aPL [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/98,99\">",
"       98,99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased incidence of arterial thrombosis may be associated with certain platelet glycoprotein polymorphisms [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic associations between two genes known to be associated with the risk of SLE (ie, STAT4 gene and BLK gene) were noted in a study of 133 patients with primary APS. However, two other SLE-associated genes were not associated with APS (ie, BANK1 gene and IRF5 gene) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVALENCE IN DIFFERENT CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their occurrence in primary APS, aPL are found in many other clinical settings. Their clinical significance varies widely in the conditions outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Healthy individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of healthy individuals have aPL. In most cases, the aPL are not present upon retesting. However, in some individuals, the presence of aPL is associated with an increased risk of developing the APS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link&amp;anchor=H60490098#H60490098\">",
"     \"Diagnosis of the antiphospholipid syndrome\", section on 'Initial laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Autoimmune and rheumatic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent rheumatic disease associated with aPL is SLE. aPL occur in a substantial proportion of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/101-104\">",
"     101-104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Approximately 31 percent of patients have an LA",
"     </li>",
"     <li>",
"      23 to 47 percent have an aCL",
"     </li>",
"     <li>",
"      20 percent have antibodies to &szlig;2-GP-I",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conversely, approximately 50 percent of patients with an LA have SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/5,103\">",
"     5,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both LAs and aCL have also been found in patients with a variety of other autoimmune and rheumatic diseases (eg, scleroderma, psoriatic arthritis) but, in the absence of clinical events associated with the APS, their significance is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/103,105\">",
"     103,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;APL have also been noted in patients with infections. These are usually IgM aCL, which may occasionally result in thrombotic events [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/103,106\">",
"     103,106",
"    </a>",
"    ]. Furthermore, these antibodies usually do not have anti-&szlig;2-GP-I antibody activity [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infections that have been associated with aPL include [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/105,107-115\">",
"     105,107-115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial infections &mdash; Bacterial septicemia, leptospirosis, syphilis, Lyme disease (borreliosis), tuberculosis, leprosy, infective endocarditis, post-streptococcal rheumatic fever, and Klebsiella infections.",
"     </li>",
"     <li>",
"      Viral infections &mdash; Hepatitis A, B, and C, mumps, HIV, HTLV-I, cytomegalovirus, varicella-zoster, Epstein-Barr virus, adenovirus parvovirus, and rubella. Several earlier studies had reported an association between infection with hepatitis C virus and aPL [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/110-112\">",
"       110-112",
"      </a>",
"      ]. However, more recent studies suggest no link between the two disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/113\">",
"       113",
"      </a>",
"      ]. As a result, the correlation between hepatitis C virus infection and aPL, if present, is weak and may not have underlying pathogenic significance.",
"     </li>",
"     <li>",
"      Parasitic infections &mdash; Malaria, Pneumocystis jirovecii, and visceral leishmaniasis (also known as kala-azar).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications have been associated with aPL. These include phenothiazines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    , alpha interferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/2/35878?source=see_link\">",
"     chlorothiazide",
"    </a>",
"    , oral contraceptives, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/105,106,116\">",
"     105,106,116",
"    </a>",
"    ]. The aPL are usually transient, often of the IgM isotype, and rarely associated with thrombosis. The mechanism of drug-induced aPL is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associations with malignant neoplasms have been reported including solid tumors of the lung, colon, cervix, prostate, kidney, ovary, breast, and bone; with Hodgkin's and non-Hodgkin lymphomas; and with myelofibrosis, polycythemia vera, myeloid and lymphocytic leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;APL have been noted in association with immune thrombocytopenia, sickle cell anemia, pernicious anemia, diabetes mellitus, inflammatory bowel disease, dialysis, and Klinefelter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35081/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    The antiphospholipid antibody syndrome (APS) is defined by two major components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence in the plasma of at least one type of autoantibody known as an antiphospholipid antibody (aPL).",
"     </li>",
"     <li>",
"      The occurrence of at least one clinical feature: either venous or arterial thromboses, or pregnancy morbidity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the clinical manifestations of APS occur in other disease populations, in the APS they occur by definition in the context of aPL. aPL, which are directed against plasma proteins bound to anionic phospholipids, may be detected as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lupus anticoagulants",
"     </li>",
"     <li>",
"      Anticardiolipin antibodies",
"     </li>",
"     <li>",
"      Antibodies to &szlig;2 glycoprotein-I",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to aCL, LAs, and antibodies to &szlig;2-GP-I, other antibodies have been reported to be associated with thrombosis. Their relevance in the APS remains uncertain. Antiprothrombin antibodies may be associated with a bleeding tendency as well as thrombosis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Additional aPL'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The pathogenesis of the APS associated clinical manifestations appears to result from a variety of aPL effects upon pathways of coagulation, including the procoagulant actions of these antibodies upon protein C, annexin V, platelets, and fibrinolysis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most commonly accepted explanation for the development of aPL is that they occur in susceptible individuals following incidental exposure to infectious agents. However, aside from the milieu of rheumatic diseases such as SLE, the conditions creating such susceptibility remain largely undefined.",
"   </p>",
"   <p>",
"    Current thinking about the pathogenesis of the APS holds that once aPL are present, a \"second-hit\" is required for the development of the full-blown syndrome.",
"   </p>",
"   <p>",
"    Multiple in vitro experiments suggest that antibodies to &szlig;2-GP-I play an important role in the APS. Findings in a mouse model of APS provide evidence that complement activation is critical for APS pregnancy complications.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/1\">",
"      Roubey RA. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/2\">",
"      Ichikawa K, Khamashta MA, Koike T, et al. beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/3\">",
"      Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/4\">",
"      Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86:3685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/5\">",
"      Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/6\">",
"      Sammaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997; 40:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/7\">",
"      Gallart T, Benito C, Reverter JC, et al. True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. Br J Haematol 2002; 116:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/8\">",
"      Sammaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arthritis Rheum 1990; 20:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/9\">",
"      Santoro SA. Antiphospholipid antibodies and thrombotic predisposition: underlying pathogenetic mechanisms. Blood 1994; 83:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/10\">",
"      Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other \"antiphospholipid\" autoantibodies. Blood 1994; 84:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/11\">",
"      Rauch J. Lupus anticoagulant antibodies: recognition of phospholipid-binding protein complexes. Lupus 1998; 7 Suppl 2:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/12\">",
"      Passam F, Krilis S. Laboratory tests for the antiphospholipid syndrome: current concepts. Pathology 2004; 36:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/13\">",
"      Urbanus RT, de Laat HB, de Groot PG, Derksen RH. Prolonged bleeding time and lupus anticoagulant: a second paradox in the antiphospholipid syndrome. Arthritis Rheum 2004; 50:3605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/14\">",
"      Orlando E, Cortelazzo S, Marchetti M, et al. Prolonged bleeding time in patients with lupus anticoagulant. Thromb Haemost 1992; 68:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/15\">",
"      Asherson RA, Khamashta MA, Ordi-Ros J, et al. The \"primary\" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/16\">",
"      Mackworth-Young CG, Loizou S, Walport MJ. Antiphospholipid antibodies and disease. Q J Med 1989; 72:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/17\">",
"      Harris EN, Gharavi A, Asherson RA, et al. Antiphospholipid antibodies--middle aged but robust. J Rheumatol 1994; 21:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/18\">",
"      Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/19\">",
"      Schousboe I. beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/20\">",
"      Nimpf J, Bevers EM, Bomans PH, et al. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta 1986; 884:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/21\">",
"      Day HM, Thiagarajan P, Ahn C, et al. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998; 25:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/22\">",
"      Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun 2000; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/23\">",
"      Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996; 5:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/24\">",
"      Puurunen M, Vaarala O, Julkunen H, et al. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996; 80:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/25\">",
"      Kalashnikova LA, Korczyn AD, Shavit S, et al. Antibodies to prothrombin in patients with Sneddon's syndrome. Neurology 1999; 53:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/26\">",
"      Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003; 48:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/27\">",
"      Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005; 93:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/28\">",
"      Zanon E, Saggiorato G, Ramon R, et al. Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost 2004; 91:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/29\">",
"      Forastiero R, Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 2008; 17:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/30\">",
"      Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus 2008; 17:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/31\">",
"      Chen PP, Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/32\">",
"      Rand JH, Wu XX, Quinn AS, Taatjes DJ. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 2008; 17:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/33\">",
"      Raschi E, Borghi MO, Grossi C, et al. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008; 17:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/34\">",
"      Cockrell E, Espinola RG, McCrae KR. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus 2008; 17:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/35\">",
"      Kinev AV, Roubey RA. Tissue factor in the antiphospholipid syndrome. Lupus 2008; 17:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/36\">",
"      Bu C, Gao L, Xie W, et al. beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum 2009; 60:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/37\">",
"      Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004; 136:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/38\">",
"      Erkan D, Lockshin MD. What is antiphospholipid syndrome? Curr Rheumatol Rep 2004; 6:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/39\">",
"      Merrill JT, Zhang HW, Shen C, et al. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999; 81:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/40\">",
"      Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med 1996; 47:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/41\">",
"      Male C, Mitchell L, Julian J, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/42\">",
"      Galli M, Willems GM, Rosing J, et al. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005; 129:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/43\">",
"      Hurtado V, Montes R, Gris JC, et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood 2004; 104:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/44\">",
"      Yoshida K, Arai T, Kaburaki J, et al. Restricted T-cell receptor beta-chain usage by T cells autoreactive to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood 2002; 99:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/45\">",
"      De Jong A, Ziboh V, Robbins D. Antiphospholipid antibodies and platelets. Curr Rheumatol Rep 2000; 2:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/46\">",
"      Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/47\">",
"      Vlachoyiannopoulos PG, Mavragani CP, Bourazopoulou E, et al. Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus. Thromb Haemost 2004; 92:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/48\">",
"      Yellin MJ, Brett J, Baum D, et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med 1995; 182:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/49\">",
"      Silver RK, Mullen TA, Caplan MS, et al. Inducible platelet adherence to human umbilical vein endothelium by anticardiolipin antibody-positive sera. Am J Obstet Gynecol 1995; 173:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/50\">",
"      Nojima J, Kuratsune H, Suehisa E, et al. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004; 91:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/51\">",
"      Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50:2911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/52\">",
"      Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/53\">",
"      Del Papa N, Guidali L, Spatola L, et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/54\">",
"      Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/55\">",
"      Hamid C, Norgate K, D'Cruz DP, et al. Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 2007; 66:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/56\">",
"      Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/57\">",
"      Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003; 12:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/58\">",
"      Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/59\">",
"      Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196:167.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/60\">",
"      Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 1991; 88:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/61\">",
"      Bakimer R, Fishman P, Blank M, et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/62\">",
"      Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/63\">",
"      Gharavi AE, Wilson W, Pierangeli S. The molecular basis of antiphospholipid syndrome. Lupus 2003; 12:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/64\">",
"      Giles IP, Isenberg DA, Latchman DS, Rahman A. How do antiphospholipid antibodies bind beta2-glycoprotein I? Arthritis Rheum 2003; 48:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/65\">",
"      Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009; 68:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/66\">",
"      Cabral AR, Cabiedes J, Alarc&oacute;n-Segovia D. Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995; 22:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/67\">",
"      Cabiedes J, Cabral AR, Alarc&oacute;n-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/68\">",
"      Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/69\">",
"      Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996; 39:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/70\">",
"      Galli M, Finazzi G, Norbis F, et al. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999; 81:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/71\">",
"      Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/72\">",
"      Cuadrado MJ, L&oacute;pez-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/73\">",
"      L&oacute;pez-Pedrera C, Cuadrado MJ, Her&aacute;ndez V, et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum 2008; 58:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/74\">",
"      Jones DW, MacKie IJ, Gallimore MJ, Winter M. Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol 2001; 113:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/75\">",
"      Bidot CJ, Jy W, Horstman LL, et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003; 120:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/76\">",
"      Shibata S, Harpel PC, Gharavi A, et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83:2532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/77\">",
"      Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/78\">",
"      Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17:3159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/79\">",
"      Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/80\">",
"      Gromnica-Ihle E, Sch&ouml;ssler W. Antiphospholipid syndrome. Int Arch Allergy Immunol 2000; 123:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/81\">",
"      Cesarman-Maus G, R&iacute;os-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006; 107:4375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/82\">",
"      Satoh A, Suzuki K, Takayama E, et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999; 26:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/83\">",
"      Song KS, Park YS, Kim HK. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2000; 43:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/84\">",
"      Bertolaccini ML, Sanna G, Ralhan S, et al. Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost 2003; 90:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/85\">",
"      Mu&ntilde;oz-Rodr&iacute;guez FJ, Reverter JC, Font J, et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 2000; 85:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/86\">",
"      Tektonidou MG, Petrovas CA, Ioannidis JP, et al. Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. Eur J Clin Invest 2000; 30:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/87\">",
"      Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/88\">",
"      Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/89\">",
"      Ambrozic A, Bozic B, Kveder T, et al. Budding, vesiculation and permeabilization of phospholipid membranes-evidence for a feasible physiologic role of beta2-glycoprotein I and pathogenic actions of anti-beta2-glycoprotein I antibodies. Biochim Biophys Acta 2005; 1740:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/90\">",
"      Morel O, Jesel L, Freyssinet JM, Toti F. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Thromb J 2005; 3:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/91\">",
"      Brouwer JL, Bijl M, Veeger NJ, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/92\">",
"      Nojima J, Kuratsune H, Suehisa E, et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/93\">",
"      Goldberg SN, Conti-Kelly AM, Greco TP. A family study of anticardiolipin antibodies and associated clinical conditions. Am J Med 1995; 99:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/94\">",
"      Schur PH. Genetics of systemic lupus erythematosus. Lupus 1995; 4:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/95\">",
"      Lundstr&ouml;m E, Gustafsson JT, J&ouml;nsen A, et al. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/96\">",
"      Karassa FB, Bijl M, Davies KA, et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003; 48:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/97\">",
"      Jim&eacute;nez S, T&agrave;ssies D, Espinosa G, et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis 2008; 67:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/98\">",
"      Hirose N, Williams R, Alberts AR, et al. A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum 1999; 42:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/99\">",
"      Sanchez ML, Katsumata K, Atsumi T, et al. Association of HLA-DM polymorphism with the production of antiphospholipid antibodies. Ann Rheum Dis 2004; 63:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/100\">",
"      Yin H, Borghi MO, Delgado-Vega AM, et al. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009; 60:2468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/101\">",
"      Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/102\">",
"      Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/103\">",
"      McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/104\">",
"      Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999; 28:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/105\">",
"      Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology 2003; 207:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/106\">",
"      Triplett DA. Many faces of lupus anticoagulants. Lupus 1998; 7 Suppl 2:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/107\">",
"      McNally T, Purdy G, Mackie IJ, et al. The use of an anti-beta 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/108\">",
"      Santiago M, Martinelli R, Ko A, et al. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. Clin Exp Rheumatol 2001; 19:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/109\">",
"      Garc&iacute;a Monc&oacute; JC, Wheeler CM, Benach JL, et al. Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides. J Neurol Sci 1993; 117:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/110\">",
"      Prieto J, Yuste JR, Beloqui O, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996; 23:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/111\">",
"      Matsuda J, Saitoh N, Gotoh M, et al. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995; 90:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/112\">",
"      Leroy V, Arvieux J, Jacob MC, et al. Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C. Br J Haematol 1998; 101:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/113\">",
"      Mu&ntilde;oz-Rodr&iacute;guez FJ, T&agrave;ssies D, Font J, et al. Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. J Hepatol 1999; 30:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/114\">",
"      Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/115\">",
"      Von Landenberg P, Lehmann HW, Kn&ouml;ll A, et al. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 2003; 48:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35081/abstract/116\">",
"      Merrill JT, Shen C, Gugnani M, et al. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24:1083.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4676 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35081=[""].join("\n");
var outline_f34_16_35081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIPHOSPHOLIPID ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anticardiolipin antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - False positive serologic test for syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lupus anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Prolongation of clotting times",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Abnormal bleeding times",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anti-&szlig;2-glycoprotein-I antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Additional aPL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antiprothrombin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      In vitro experiments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Interaction with other antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Microparticles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      GENETIC PREDISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVALENCE IN DIFFERENT CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Healthy individuals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Autoimmune and rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_16_35082="Complications and management of the mucopolysaccharidoses";
var content_f34_16_35082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications and management of the mucopolysaccharidoses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35082/contributors\">",
"     Emil Kakkis, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35082/contributors\">",
"     Ed Wraith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35082/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35082/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35082/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/16/35082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/16/35082/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/16/35082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes required for the stepwise breakdown of glycosaminoglycans (GAGs), also known as mucopolysaccharides. These conditions are differentiated by their clinical features and age of presentation (",
"    <a class=\"graphic graphic_table graphicRef57733 \" href=\"UTD.htm?34/41/35485\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The complications associated with the mucopolysaccharidoses and their management are reviewed here. The clinical features and diagnosis of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"     \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESPIRATORY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory complications affect patients with all types of MPS and contribute to death and disability as their disease progresses. Respiratory abnormalities result from airway obstruction, excessive secretions, skeletal restriction, organomegaly, frequent infections, and neurologic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These problems can lead to progressive respiratory insufficiency, severe sleep apnea, and sudden death from central apnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Central apnea from cord compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPS IV A and IV B patients are especially prone to high cord compression due to atlantoaxial instability and odontoid dysplasia, although this complication also occurs in other types. This condition may result in depressed respiration or sudden respiratory arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Prophylactic cervical fusion is recommended in MPS IV patients and in other patients with cervical instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MPS I, II, VI, and VII often develop upper airway obstruction due to an enlarged tongue, thickened gums, and engorged soft tissues of the nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/1,2,7-10\">",
"     1,2,7-10",
"    </a>",
"    ]. Increased tonsillar and adenoid size due to storage in lymphatic tissue also contributes to obstruction. Upper airway obstruction may be exacerbated in certain positions (eg, raising the arms may result in obstruction of the thoracic inlet, causing facial plethora, distension of the neck veins, and shortness of breath) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/11\">",
"     11",
"    </a>",
"    ]. Airway problems may be worsened by excessive thick secretions due to chronic or recurrent ear and sinus infections. Progressive obstruction can result in sleep apnea with severe hypoxemia and right heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/1,2,12,13\">",
"     1,2,12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9801?source=see_link\">",
"     \"Mechanisms and predisposing factors for sleep related breathing disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tracheal or lower airway obstruction can result from malformed and floppy tracheal cartilage, redundant respiratory epithelium, or pedunculated nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/7,14-16\">",
"     7,14-16",
"    </a>",
"    ]. Reactive airway disease is common. In the setting of airway compromise, minor upper respiratory infections or pneumonia can cause severe reactive airway disease and airway edema. In patients with advanced disease, this may lead to sudden respiratory arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions are primarily directed at maintaining a stable airway. Removal of the tonsils and adenoids can temporarily reduce airway obstruction and sleep apnea, but these problems often recur [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/9,12,17\">",
"     9,12,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of obstructive sleep apnea in children\", section on 'Adenotonsillectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper airway obstruction, especially when associated with sleep apnea, may be improved by continuous positive airway pressure (CPAP) applied at night [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/9\">",
"     9",
"    </a>",
"    ]. Younger patients seem to adapt better to CPAP than older ones. However, facial dysmorphism may make it difficult to achieve the proper fit of masks. Bilevel positive airway pressure ventilators (BiPAP devices), which decrease pressure during exhalation and increase pressure during inhalation, may be better tolerated by some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of obstructive sleep apnea in children\", section on 'Positive airway pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supplemental oxygen at low flow rates can be used to treat arterial desaturation during sleep. However, oxygen therapy should be used with caution to avoid suppressing hypoxic respiratory drive. Patients with severe hypoxemia, hypercapnia, and sleep disturbance may require tracheotomy. Although families initially may resist tracheotomy, it often is the best approach to maintaining an adequate airway. Tracheotomy should be performed in patients with signs of right heart failure, severe sleep apnea that cannot be improved with CPAP, or critical airway stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of obstructive sleep apnea in children\", section on 'Positive airway pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MPS often have complications during general anesthesia. These are primarily due to the presence of airway obstruction, excessive secretions, a large tongue, and abnormal airway anatomy, resulting in extreme difficulty in endotracheal intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/7,18-22\">",
"     7,18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk for difficult intubation may be increased in older patients or those with sleep apnea or other signs of airway obstruction. In one report in 30 MPS patients who were anesthetized 141 times, preoperative signs of airway obstruction were present more often in patients with moderate to severe postoperative airway complications, compared with those with mild or no complications (78 versus 23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/7\">",
"     7",
"    </a>",
"    ]. Extension of the neck may cause spinal cord injury due to instability of the cervical spine, increasing the difficulty of intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/4,23\">",
"     4,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These problems should be weighed carefully in making decisions about surgical procedures. Anesthesia should be administered at centers experienced in the management of MPS patients. A comprehensive plan should be made before performing general anesthesia, including management options if complications develop. Local or regional anesthesia should be used whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/7,18,19,24,25\">",
"     7,18,19,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If general anesthesia is unavoidable, bronchoscopic intubation using an endotracheal tube smaller than indicated by the patient's age or weight may help with airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. Attempts to intubate without adequate visualization can lead to injury of the laryngeal tissue and airway edema.",
"   </p>",
"   <p>",
"    Extubation may be very difficult in MPS patients, and corticosteroids or other medications may be needed to reduce airway edema. Not uncommonly, a patient cannot be successfully extubated, and an unplanned tracheotomy must be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sinopulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPS patients have frequent or chronic pulmonary infections, otitis media, and sinusitis in the first few years after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/1,9,12,17\">",
"     1,9,12,17",
"    </a>",
"    ]. The associated thick and copious secretions can worsen airway obstruction. Minor respiratory infections often progress to pneumonia with consolidation, and require hospitalization.",
"   </p>",
"   <p>",
"    Obstruction of the Eustachian tubes and sinus ostia contribute to the persistence of infections. Another possible mechanism for increased infection is abnormal immune function, which has been demonstrated in an animal model. T cell proliferative response and antibody production were decreased in a murine model of MPS VII after antigen challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/27\">",
"     27",
"    </a>",
"    ]. Whether this occurs in humans with MPS is not known, although the frequency and severity of sinopulmonary infections is consistent with this finding.",
"   </p>",
"   <p>",
"    The antimicrobial management of infections is similar to those without associated MPS. However, recovery time may be longer for MPS patients, and bronchodilators may be needed to treat reactive airway disease. Otitis media may also be more difficult to treat, and tympanostomy tubes may be required. Tube placement should be considered more readily than in patients without MPS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preventive measures include influenza vaccine, in addition to standard childhood immunizations. Prophylactic antibiotic treatment has been used, especially during the winter, and nebulized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    has been used for prophylaxis in patients with tracheotomies. However, the efficacy of these approaches in MPS is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CARDIAC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac abnormalities may result from the underlying MPS disorder or as a complication of severe pulmonary disease and associated chronic hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/28\">",
"     28",
"    </a>",
"    ]. Cardiomyopathy and endocardial fibroelastosis occur rarely in young severely affected patients with Hurler syndrome and MPS VI [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Cardiac problems may be complicated by coronary artery and other vascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive thickening of the mitral and aortic valves causing insufficiency occurs often in MPS, especially in types I, II, and VI, and less commonly in MPS III A&ndash;D [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/2,9,32\">",
"     2,9,32",
"    </a>",
"    ]. In one series of 84 MPS patients, mitral and aortic regurgitation were detected in 64 and 41 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/33\">",
"     33",
"    </a>",
"    ]. Tricuspid and pulmonic valve regurgitation also occur and may be exacerbated by pulmonary hypertension.",
"   </p>",
"   <p>",
"    Although regurgitation can be detected in young patients, progressive worsening of valvular competence typically results in heart failure in late school age or in the teens [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/1,33,34\">",
"     1,33,34",
"    </a>",
"    ]. Severely affected patients may require valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with valvular insufficiency, systemic hypertension due to aortic coarctation and other vascular disease can result in further compromise and should be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/38\">",
"     38",
"    </a>",
"    ]. It is uncertain whether prophylactic afterload reduction is beneficial in patients with moderate regurgitation and without hypertension. This approach has been used successfully to treat the cardiovascular manifestations of Marfan syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Storage cells accumulate in the walls of arterial blood vessels, including the coronary arteries, leading to impaired flow and ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The coronary lesions involve the entire course of the vessels. Obstruction may result in sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/39\">",
"     39",
"    </a>",
"    ]. Vigilance is required to detect coronary disease, as it is usually unexpected in young children. Furthermore, the clinical presentation may not be typical, and coronary angiography may not predict the severity of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intimal lesions can result in narrowing of the abdominal aorta, causing hypertension and poor perfusion of the lower extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/38\">",
"     38",
"    </a>",
"    ]. Arteriopathy also affects other vessels, including the renal, mesenteric, and iliac arteries. Narrowing can be detected by arteriography, ultrasound, and magnetic resonance imaging (MRI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hypoxemia due to airway obstruction and pulmonary disease can lead to pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Pulmonary hypertension may exacerbate right heart failure caused by mitral valve regurgitation. Therapy should be directed at maintaining a secure airway and avoiding hypoxemia, especially during the night.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SKELETAL AND CONNECTIVE TISSUE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Storage material in cells that form the connective tissues leads to abnormalities in bone, joints, and ligaments. These problems interfere with growth, cause dysmorphism, impair mobility, and cause pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dysostosis multiplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The constellation of characteristic bony abnormalities is known as dysostosis multiplex. This condition occurs in MPS I, II, VI, and VII, and is less extensive in MPS III and milder variants [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/2,9,41\">",
"     2,9,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiographic findings of dysostosis multiplex include a thickened hyperostotic calvarium, often with craniosynostosis; a \"J\" or \"shoe-shaped\" sella turcica (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75624 \" href=\"UTD.htm?6/35/6719\">",
"     image 1",
"    </a>",
"    ); odontoid dysplasia; ovoid and beaked vertebrae (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52046 \" href=\"UTD.htm?18/41/19103\">",
"     image 2",
"    </a>",
"    ); \"oar-shaped\" ribs with narrow roots and broadened ends (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50673 \" href=\"UTD.htm?40/2/41007\">",
"     image 3",
"    </a>",
"    ); tilting of the radial and ulnar epiphyses (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51207 \" href=\"UTD.htm?23/40/24207\">",
"     image 4",
"    </a>",
"    ); long bones with irregular, curved, and expanded diaphyses (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51207 \" href=\"UTD.htm?23/40/24207\">",
"     image 4",
"    </a>",
"    ); pointed and irregular metacarpals (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63875 \" href=\"UTD.htm?18/6/18543\">",
"     image 5",
"    </a>",
"    ); irregular or dysplastic femoral capital epiphyses; and a dysplastic pelvis. The basilar skull may impress upon or fuse with the cervical vertebrae; this is associated with a narrowed spinal canal [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Cervical cord compression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The bone disease in Morquio patients (MPS IV A and IV B) begins with ovoid vertebrae and typical features of dysostosis multiplex, and progresses with age to appear similar to spondyloepiphyseal dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/44\">",
"     44",
"    </a>",
"    ]. The ovoid vertebrae flatten and collapse, resulting in distinctive platyspondyly (thin flat vertebral bodies). Deficient ossification of the superior acetabulum may result in progressive dislocation of the hip joint and erosions of the femoral neck. Joint replacement surgery is possible using a standard prosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distinctive skeletal findings may help with diagnosis. As an example, the abnormal ovoid or beaked vertebral bodies and the oar-shaped ribs may be noted on a chest radiograph of an affected infant who has recurrent pneumonia. This would lead to further diagnostic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of the mucopolysaccharidoses\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Spine abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the vertebral bodies occur frequently and can result in spinal instability and kyphoscoliosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Odontoid hypoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoplasia or dysplasia of the odontoid is a characteristic finding in MPS IV A and IV B and is common in the severe forms of MPS I and VII. Hypoplasia is due in part to inadequate ossification, although reossification may occur after cervical fusion. Odontoid hypoplasia can lead to atlantoaxial instability, which can result in C1-C2 subluxation and high spinal cord compression [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/3,46,47\">",
"     3,46,47",
"    </a>",
"    ]. Patients with MPS IV A and IV B should have prophylactic cervical vertebral fusion to prevent progressive cord compression and sudden death after a minor fall. Other MPS patients, especially those with MPS I and MPS VII, should be evaluated with radiographs in flexion and extension. If cervical instability is present, fusion should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Subluxation and kyphoscoliosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral subluxation and kyphoscoliosis can occur throughout the spinal column, although they usually occur at points of transition (cervicothoracic, thoracolumbar, and lumbosacral junctions). The causes of kyphoscoliosis include dysplastic vertebral bodies (beaked vertebrae), subluxation (which results in part from ligamentous laxity), and compression or deformation of the vertebral bodies. Subluxation can compromise the cord at any level.",
"   </p>",
"   <p>",
"    Patients with Hurler syndrome often develop a gibbus deformity of the lumbar spine, characterized by anterior wedging and posterior displacement of the vertebrae at the peak of the curve (",
"    <a class=\"graphic graphic_picture graphicRef75426 \" href=\"UTD.htm?40/21/41311\">",
"     picture 1",
"    </a>",
"    ), resulting in a beaked appearance on lateral radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52046 \" href=\"UTD.htm?18/41/19103\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/48\">",
"     48",
"    </a>",
"    ]. The causes of gibbus formation include incomplete ossification of the abnormal vertebrae, poor truncal tone, disturbed growth, anterior disc herniation, and weight-bearing. Spondylolisthesis (slippage of",
"    <span class=\"nowrap\">",
"     L5/S1)",
"    </span>",
"    occurs in the majority of patients with less severe forms of MPS I.",
"   </p>",
"   <p>",
"    Spinal fusion surgery may be required to stabilize the spine [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/41,49\">",
"     41,49",
"    </a>",
"    ]. However, MPS patients do not heal well and often have complications from surgical procedures. Spinal fusion often fails and must be repeated. One cause of poor results is that severe osteopenia may lead to failure of internal fixation hardware. The use of membranous (skull) rather than endochondral bone as grafts for fusion may improve outcome, because the former appears to be less severely affected in MPS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/49\">",
"     49",
"    </a>",
"    ]. Fusion surgery should be carefully considered and performed only when absolutely necessary. The goal of the procedure should be the minimum necessary to stabilize the spine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Genu valgum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in the growth plates and epiphyses are caused by mucopolysaccharide storage in the chondrocytes. In the knee, storage may lead to inadequate growth in the medial part of the tibial growth plate, causing genu valgum, or knock-knee deformity. This abnormality occurs in the majority of patients with MPS IV A and IV B, but can occur in other types. Severe cases require osteotomy and straightening procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. These procedures should be delayed until after age 10 years, if possible, because earlier operations often need to be repeated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6199?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the child with knock-knees\", section on 'Pathologic knock-knees'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other bones often affected include the femoral epiphyses. Patients can develop degenerative hip disease, which is painful and debilitating. Slanted or irregular epiphyses, often seen in the distal ulna and radius, are characteristic findings on radiographs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Short stature",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extensive skeletal abnormalities impair growth and result in short stature. Growth hormone resistance may also play a role in patients with MPS I [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/52\">",
"     52",
"    </a>",
"    ]. Although patients with severe MPS I may have accelerated growth in the first year, height attained is typically less than the fifth percentile. Less severely affected children may reach normal or near-normal heights. Patients with MPS II have accelerated growth the first three years of life, but subsequently have decreased growth velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/53\">",
"     53",
"    </a>",
"    ]. The adolescent growth spurt occurs earlier in boys with MPS II. Enzyme replacement therapy may improve growth in patients with MPS II, particularly if therapy is started before 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Joint stiffness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint stiffness associated with pain on movement occurs in nearly all MPS patients. The etiology of the stiffness includes inflammatory changes, engorgement of the synovial and other connective tissues of the joint, and abnormalities of the cartilage and epiphyseal bone [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Pain and decreased movement can lead to development of contractures (",
"    <a class=\"graphic graphic_picture graphicRef64899 \" href=\"UTD.htm?2/13/2271\">",
"     picture 2",
"    </a>",
"    ). This progression may be hastened in some patients by poor neurologic function.",
"   </p>",
"   <p>",
"    Physical therapy can improve flexibility of the joints and help maintain function. However, it cannot prevent the inexorable decline in joint mobility. Wheelchairs are often needed for mobility even in patients who can walk, because of pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limited endurance. Animal studies suggest a possible therapeutic role for TNF-alpha antagonists, but additional studies are necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ligamentous laxity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although lysosomal storage causes some joints to be stiff, mucopolysaccharide accumulation in ligaments can lead to laxity of other joints. This is seen most often in MPS IV A and IV B [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/58\">",
"     58",
"    </a>",
"    ]. Ligamentous laxity contributes to atlantoaxial instability and the development of kyphoscoliosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inguinal and umbilical hernias resulting from connective tissue abnormalities are common, especially in MPS I, II, VI, and VII [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/2,41,59\">",
"     2,41,59",
"    </a>",
"    ]. They may occur early, as part of the initial presentation, and can become quite large [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/60\">",
"     60",
"    </a>",
"    ]. Hernias can also occur at the incision site following abdominal surgery. Hepatosplenomegaly may contribute to increased intraabdominal pressure and lead to hernia formation.",
"   </p>",
"   <p>",
"    Surgical repair of inguinal hernias often fails and needs to be repeated. Hepatosplenomegaly and the weak connective tissues may contribute to poor results. Thus, in some patients, management with trusses may be preferable to the risk of anesthesia and a surgical repair that is likely to be temporary. Large umbilical hernias that occur in MPS I should be repaired when possible, as their size can lead to breakdown of the overlying skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NEUROLOGIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications can result from storage in cells in the brain; in supporting structures, such as the meninges or spinal column; or directly in sensory organs, such as the eye. Characteristic findings on cranial MRI include arachnoid cysts, enlarged cisterna magna, cerebellar hypoplasia, encephaloceles, and linear cyst-like structures in the subcortical white matter and corpus callosum [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/61-67\">",
"     61-67",
"    </a>",
"    ]. These cysts are due to storage in the Virchow-Robin spaces around the blood vessels and are not associated with cognitive defects [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/62,68\">",
"     62,68",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74009 \" href=\"UTD.htm?18/24/18817\">",
"     image 6",
"    </a>",
"    ). Alterations of myelination may occur. Patients with increased intracranial pressure can have significant ventriculomegaly, although some have minimal or no ventricular enlargement associated with transependymal fluid shifts in the periventricular areas.",
"   </p>",
"   <p>",
"    Imaging findings may not reflect neurologic status. As an example, in MPS III A-D, the MRI findings of atrophy and delayed myelination may precede the onset of neurologic abnormalities and may not correlate with clinical progression [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/69\">",
"     69",
"    </a>",
"    ]. The loss of distinction at the interface between gray and white matter may be associated with decline in mental function [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Developmental delay and neurologic decline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental delay and progressive decline occur in severe forms of MPS I, II, III, and VII [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/2,41,70,71\">",
"     2,41,70,71",
"    </a>",
"    ]. In Hurler syndrome, delay that begins during the first year of life is often not appreciated until the second year. In most cases, affected children begin to walk and speak short sentences before reaching a developmental plateau. They then decline slowly so that the average IQ is 50 by age three to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Abnormal behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hurler patients tend to be pleasant, good-natured children with excellent behavior during this period, but often become unresponsive as the disease progresses to its final stages. In severe Hunter and Sanfilippo syndromes, developmental delay typically is noted at two to six years of age and is accompanied by hyperactive and aggressive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/71,73-76\">",
"     71,73-76",
"    </a>",
"    ]. Patients have short attention spans, do not respond to instructions, and have no sense of danger. The aggressive behavior appears to improve with age, as overall function progressively declines, usually reaching a neurologically devastated and unresponsive state in the early teenage years. Abnormal behavior in some patients may be caused by hydrocephalus with increased intracranial pressure, although the prevalence of this problem in MPS III A&ndash;D is unknown. MPS II patients can have meningeal obstruction and high-pressure hydrocephalus, causing severe headaches that may in some cases worsen the behavior problems.",
"   </p>",
"   <p>",
"    Management consists primarily of ensuring that the home environment is safe. Attempts to treat the abnormal behavior with medications have been limited by their side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/59,77\">",
"     59,77",
"    </a>",
"    ]. Medications that are sometimes used include neuroleptics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/11/7350?source=see_link\">",
"     thioridazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    ), which may cause excessive sedation; benzodiazepines, which may increase secretions and cause respiratory compromise in patients with airway problems, bulbar palsy, and decreased swallowing; and tricyclic antidepressants.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    may help control behavior; the former should be avoided in patients with seizures.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    is usually not helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures may occur in Hunter and Sanfilippo syndromes, but are rarely seen in other MPS disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/61\">",
"     61",
"    </a>",
"    ]. Electroencephalographic data in a few MPS patients with seizures demonstrate irregular slow wave activity and typical epileptiform discharges [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/61,73,79\">",
"     61,73,79",
"    </a>",
"    ]. Seizures are managed with anticonvulsant medications similar to patients without MPS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Sleep disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbance is common, especially in Sanfilippo syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Sleep becomes progressively disorganized, and patients become active around the clock.",
"   </p>",
"   <p>",
"    A padded bedroom is usually required to keep the child contained and avoid injury during the night. Restraints are generally not effective. Medications, including melatonin or sedatives, may improve sleep. Melatonin is estimated to be successful in approximately 75 percent of patients within three to four days of use. The authors start with a dose of 2 to 3 mg and increase if necessary after one to two weeks to 4 to 6 mg, with further increases as clinically indicated. Children with MPS frequently require treatment with the maximum dose of 10 mg. Melatonin is used with a strict regimen of sleep time and a darkened bedroom. Benzodiazepines or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    may also be tried.",
"   </p>",
"   <p>",
"    Sleep disturbances contribute to exhaustion of the caretakers. Respite care should be made available for the parents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Communicating hydrocephalus frequently develops in MPS I, II, III, VI, and VII [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/2,9,80-83\">",
"     2,9,80-83",
"    </a>",
"    ]. In MPS I, II, VI, and VII, the mechanism is engorgement of the arachnoid granulations by storage material, impeding resorption of cerebrospinal fluid, and increasing intracranial pressure (ICP) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75849 \" href=\"UTD.htm?15/37/15952\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/84\">",
"     84",
"    </a>",
"    ]. In MPS III patients, ventricular enlargement may be due to hydrocephalus, but more commonly is due to atrophy in the later stages of the illness. Acute increases in ICP may present with severe headaches, visual disturbances, altered mental status, and rapidly progressive developmental decline [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/80\">",
"     80",
"    </a>",
"    ]. However, the process may be insidious and without typical signs [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/41,85\">",
"     41,85",
"    </a>",
"    ]. Papilledema is not a reliable indicator and is often not present in patients with increased intracranial pressure. Swelling of the optic nerve head is frequently a precursor of optic atrophy, rather than a sign of increased ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/41,86\">",
"     41,86",
"    </a>",
"    ]. Another diagnostic pitfall is the interpretation of modest ventriculomegaly seen on MRI as cerebral atrophy rather than high-pressure communicating hydrocephalus.",
"   </p>",
"   <p>",
"    The diagnosis of hydrocephalus is confirmed by lumbar puncture with measurement of opening pressure. The disorder is usually managed by placement of a ventriculoperitoneal shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cervical cord compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression of the cervical spinal cord can result from pachymeningitis cervicalis or vertebral subluxation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Pachymeningitis cervicalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pachymeningitis cervicalis is the progressive thickening and scarring of the meninges around the cervical spinal cord caused by MPS storage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58332 graphicRef72193 \" href=\"UTD.htm?4/15/4343\">",
"     image 8A-B",
"    </a>",
"    ). The thickened meninges may form a tight sleeve around the spinal cord that impedes the flow of CSF and progressively compresses the cervical cord. This process may be compounded by a spinal canal that has been narrowed by bone disease. Pachymeningitis cervicalis was originally described in Maroteaux-Lamy syndrome (MPS VI), but has been reported in MPS I, II, and VII [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/87-89\">",
"     87-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical course is insidious. Patients may complain of fatigue in their legs and gradually have decreased movement and prefer sedentary activities. Occasional \"buckling\" of the knees may be attributed to a joint problem. Patients typically present to the clinician for evaluation as weakness or sensory loss becomes more evident. The constellation of motor and sensory defects depend upon the extent and location of the compression, and may affect breathing or bowel and bladder control.",
"   </p>",
"   <p>",
"    Management of this condition is difficult. The pressure can often be relieved by laminectomy with incision and removal of meningeal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/87,90-92\">",
"     87,90-92",
"    </a>",
"    ]. In patients with accompanying subluxation, fusion of the vertebrae is needed. A transoral approach has been used to decompress tissue anterior to the cord [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/5\">",
"     5",
"    </a>",
"    ]. Surgical treatment may be the only option in many cases. However, these procedures have high surgical and anesthesia risks, and may not offer significant benefit in some patients. To prevent serious cervical cord accidents in these patients, it is extremely important to assure that the neck is appropriately protected at all times and is not flexed or extended during intubation or surgery. Presurgical conferences to discuss management with the anesthesiologist and surgeon are necessary to assure that the neck is protected during surgical decompression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     C1&ndash;C2 subluxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontoid dysplasia and ligamentous laxity can result in subluxation of C1 on C2 and cause cord compression [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/42,47,93-95\">",
"     42,47,93-95",
"    </a>",
"    ]. The instability and frequent movement may impair ossification of the odontoid and result in thickened fibrocartilaginous tissue anterior to the cord, causing further compression [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/3,5,96\">",
"     3,5,96",
"    </a>",
"    ]. This problem is common in MPS IV A and IV B, but also occurs in MPS I, VI, and VII [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/3,61,97\">",
"     3,61,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cord compression due to subluxation is often anterior and causes predominantly motor dysfunction. Onset of motor dysfunction can be insidious, with slowly progressive and nonspecific fatigue followed by decreased activity and preference for sedentary play. If untreated, the cord compression can result in progressive ascending paresis and paralysis. Compression can be visualized with MRI, and cord injury confirmed by the presence of abnormal T2-weighted signal in the cord. Somatosensory evoked potentials of the median or posterior tibial nerves have been used to evaluate functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management includes posterior cervical fusion to stabilize the neck and reduce cord compression injury [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/3,20,42,92\">",
"     3,20,42,92",
"    </a>",
"    ]. Concomitant decompression of excess tissue anterior to the cord may be needed. This procedure should be performed prophylactically in MPS IV A and IV B to avoid sudden high cord compression and respiratory arrest following a minor fall [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/3,5,99,100\">",
"     3,5,99,100",
"    </a>",
"    ]. Surgery should be performed at centers experienced in the management of MPS. To prevent serious cervical cord accidents in these patients, it is extremely important to assure that the neck is appropriately protected at all times and is not flexed or extended during intubation or surgery. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Pachymeningitis cervicalis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve compression disorders, such as carpal tunnel syndrome, resulting from bone disease and soft tissue storage, are very common in MPS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/2,9,101-105\">",
"     2,9,101-105",
"    </a>",
"    ]. The onset of symptoms can be insidious. Specific symptoms of median nerve compression, such as pain, paresthesias, or weakness, occur rarely in affected children, leading to under-recognition of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/102,106-110\">",
"     102,106-110",
"    </a>",
"    ]. Signs including thenar atrophy, decreased sweating, claw hand deformity, and weakness are more common.",
"   </p>",
"   <p>",
"    All MPS patients should be evaluated for carpal tunnel syndrome using standard methods, such as nerve conduction studies. Treatment by carpal tunnel release results in functional improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/102\">",
"     102",
"    </a>",
"    ]. However, additional accumulation of storage material in soft tissues can lead to recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32822?source=see_link\">",
"     \"Surgery for carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Entrapment of other peripheral nerves, such as the ulnar nerve, may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. Treatment is similar to patients without MPS. Trigger finger (flexor tendon entrapment of the digit, typically due to thickening of the digit's A1 pulley) is common [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/101,113\">",
"     101,113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPS II and III patients may develop recurrent or chronic diarrhea. The mechanism is thought to be MPS storage in the neurons of the myenteric plexus, leading to abnormal motility [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/114\">",
"     114",
"    </a>",
"    ]. Although motility has not been directly studied, storage in these cells has been demonstrated in biopsies of the intestinal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/77\">",
"     77",
"    </a>",
"    ]. Diarrhea can be improved with medications that decrease bowel motility (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/31/8692?source=see_link\">",
"     loperamide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     OPHTHALMOLOGIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vision-impairing ophthalmologic complications of MPS include corneal clouding, glaucoma, optic neuropathy, and degeneration of the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/115\">",
"     115",
"    </a>",
"    ]. These complications seem to develop early in the course and often are present at the time of initial diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SPECIFIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most therapies for MPS are symptomatic and not specific for the underlying abnormality. Thus, they cannot prevent the inevitable decline in function. However, specific therapies, such as hematopoietic stem cell transplantation or enzyme replacement, may alter the natural history of these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) leads to the progressive replacement of enzyme-deficient hematopoietic cells with donor-derived enzyme-competent cells in vascular and extravascular compartments of the body [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/116\">",
"     116",
"    </a>",
"    ]. HCT has been used most successfully to treat MPS I and some mild cases of MPS II and MPS VI [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Hurler syndrome, HCT is most effective when initiated before two years of age and before the onset of significant mental regression [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/118-124\">",
"     118-124",
"    </a>",
"    ]. The white cells derived from marrow are thought to distribute in the body and secrete small amounts of enzyme that are taken up by other tissues, correcting the deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCT has been performed in more than 500 patients with Hurler syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/125\">",
"     125",
"    </a>",
"    ]. Survival rates for HCT in Hurler syndrome range from 50 to 85 percent. Successful engraftment rates range from 34 to 85 percent.",
"   </p>",
"   <p>",
"    In the majority of patients with successful engraftment, HCT reduces hepatosplenomegaly, increases joint mobility, decreases airway obstruction, improves cardiac function, decreases CSF pressure, improves or stabilizes hearing, and, especially in younger patients, may stabilize mental regression [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/117-126\">",
"     117-126",
"    </a>",
"    ]. Factors associated with improved cognitive outcome include age &lt;2 years at time of transplant, baseline mental developmental index &gt;70, and related donor with homozygous normal enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/117,118,125\">",
"     117,118,125",
"    </a>",
"    ]. The course of corneal clouding is variable; most patients have mild residual corneal clouding, but corneal transplantation is rarely required [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/125\">",
"     125",
"    </a>",
"    ]. Retinal function may decline [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/127\">",
"     127",
"    </a>",
"    ]. HCT does not correct skeletal disorders, presumably because of poor penetration of the skeletal tissues by the enzyme derived from the transplanted leukocytes, and orthopedic surgical procedures are often required [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/95,117,126,128,129\">",
"     95,117,126,128,129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report from the Storage Disease Collaborative Study Group evaluated the outcome of 54 children with Hurler syndrome who had HCT from HLA-genotypically identical sibling (GIS) or HLA-haploidentical related (HIR) donors [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/118\">",
"     118",
"    </a>",
"    ]. Engraftment followed the initial HCT in 72 percent of patients. The actuarial probability of survival at five years was 64 percent for all patients, and 75, 53, and 53 percent for those with GIS, HIR, and donor engraftment, respectively. Graft-versus-host disease occurred more frequently in HIR than GIS patients (acute, 55 versus 32 percent; chronic, 24 versus 0 percent). Development was normal or somewhat slower than normal in 9 of 14 patients transplanted before 24 months of age, compared with 3 of 12 patients transplanted after 24 months. Normal cognitive development was more likely in patients with a mental developmental index &gt;70 at baseline and who had a successful HCT from a related donor with homozygous normal enzyme activity.",
"   </p>",
"   <p>",
"    Enzyme replacement therapy (ERT,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=see_link\">",
"     laronidase",
"    </a>",
"    ) is used in many transplantation centers to stabilize or improve the clinical status of patients with MPS I before and a short time after HCT. In patients with MPS I and cardiomyopathy, enzyme replacement therapy before HCT may be life-saving [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/130-132\">",
"     130-132",
"    </a>",
"    ]. In one series of 18 patients in whom laronidase was continued until donor cell engraftment, the survival and engraftment rate was 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/132\">",
"     132",
"    </a>",
"    ]. The use of laronidase was not associated with increased risk of graft-versus-host disease or graft failure. The use of ERT before HCT and until donor engraftment in patients with Hurler syndrome is also associated with improved cognitive outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/133\">",
"     133",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'MPS I'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    HCT has also improved the clinical outcomes of patients with milder MPS I and II, and MPS VI and VII [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/134-138\">",
"     134-138",
"    </a>",
"    ]. However, HCT does not prevent the CNS decline in patients with severe MPS II and does not appear to be successful in other types [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/117\">",
"     117",
"    </a>",
"    ]. MPS III A-D patients usually do not benefit and may worsen after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/72,139\">",
"     72,139",
"    </a>",
"    ]. HCT does not correct the bony abnormalities in MPS IV A and IV B or MPS I. The reason for the lack of success of HCT in some types of MPS is uncertain, although it is possible that the transplanted cells do not secrete sufficient enzyme, or the enzyme may not be taken up sufficiently to correct the deficiency.",
"   </p>",
"   <p>",
"    HCT is routinely offered only to MPS patients with Hurler syndrome under approximately two years of age. It is less commonly used in mild MPS II, MPS VI, and MPS VII. Parents should be extensively counseled regarding the available evidence on clinical outcomes and the considerable risks of the procedure. After counseling, some parents choose not to undertake this procedure while others are willing to proceed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Cord blood transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical cord blood from related or unrelated donors is another potential source for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/117,125,140,141\">",
"     117,125,140,141",
"    </a>",
"    ]. The advantage of cord blood transplants is the ease of finding a donor, which has increased the availability of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The feasibility of unrelated donor cord blood transplantation without total body irradiation for children with Hurler syndrome (MPS I H) was evaluated in 20 children at a median age of 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/141\">",
"     141",
"    </a>",
"    ]. Neutrophil engraftment occurred between 10 and 39 days after transplant (median 24 days). Three children died (one of idiopathic hyperammonemia, and two from complications of cytomegalovirus infection). All of the survivors had complete donor chimerism and normal peripheral blood alpha-L-iduronidase at a median of 905 days after transplantation. Transplantation improved neurocognitive performance and growth velocity, and stabilized or improved bony disease. Five patients had grade II or III graft-versus-host disease, but none more severe. Long-term follow-up is necessary to determine the full effect of cord blood transplantation on the natural history of MPS I H.",
"   </p>",
"   <p>",
"    Engraftment and survival rates are similar with cord blood, bone marrow, and peripheral blood transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/142\">",
"     142",
"    </a>",
"    ]. However, more patients who receive cord blood achieve full donor chimerism (93 versus 66 percent) and normal enzyme levels (100 versus 60 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Enzyme replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzyme replacement therapy is approved in the United States for patients with MPS I, MPS II, and MPS VI [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     MPS I",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with MPS I (Hurler, Hurler-Scheie, and Scheie syndromes), treatment with recombinant human alpha-L-iduronidase (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=see_link\">",
"     laronidase",
"    </a>",
"    ), the deficient enzyme, reduces lysosomal storage in the liver and improves some clinical manifestations and stabilizes others [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/144-146\">",
"     144-146",
"    </a>",
"    ]. Better outcome is achieved if laronidase is initiated before serious complications occur [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=see_link\">",
"     Laronidase",
"    </a>",
"    (Aldurazyme) is approved in the United States for patients with Hurler and Hurler-Scheie forms of MPS I and for patients with the Scheie form who have moderate to severe symptoms. In the European Union, it is indicated to treat the nonneurologic aspects of confirmed MPS I [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approval of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=see_link\">",
"     laronidase",
"    </a>",
"    was based upon a phase III study in 45 patients with MPS I [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/145\">",
"     145",
"    </a>",
"    ]. In this trial, patients were randomly assigned to weekly intravenous infusions of laronidase or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/145\">",
"     145",
"    </a>",
"    ]. After 26 weeks of therapy, patients in the laronidase group compared with those in the placebo group had improved forced vital capacity (FVC) and walking distance, and reduced hepatomegaly and urinary glycosaminoglycan (GAGs) levels. In addition, laronidase improved sleep apnea and shoulder flexion among the more severely affected patients.",
"   </p>",
"   <p>",
"    All 45 patients were enrolled in a 3.5-year open-label extension study, which 40 completed [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/148\">",
"     148",
"    </a>",
"    ]. As in earlier trials, urinary glycosaminoglycan levels decreased within the first 12 weeks and liver volume within the first year. Stabilization or improvement was also noted in percent predicted forced vital capacity, six-minute walk test, sleep apnea, shoulder flexion, and activities of daily living. Corneal clouding did not change appreciably. Infusion reactions were generally mild and decreased after six months. Although 93 percent of patients developed antibodies to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=see_link\">",
"     laronidase",
"    </a>",
"    , 29 percent were seronegative at their last assessment.",
"   </p>",
"   <p>",
"    Similar findings (including normalized liver size, further increased range of motion, increased height and weight growth, and improved airway size) were noted in a series of 10 patients at one year and in five of those patients at six years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/144,146,149\">",
"     144,146,149",
"    </a>",
"    ]. The five patients had some worsening of preexisting neurologic symptoms, and carpal tunnel syndrome still required release. Patients with substantial valvular disease at baseline continued to progress, needing valve replacement, but those with mild or minimal disease may have stabilized. At the six-year follow-up, 4 of the original 10 patients had died of various causes, including two with postsurgical complications for preexisting problems.",
"   </p>",
"   <p>",
"    The safety and efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/884?source=see_link\">",
"     laronidase",
"    </a>",
"    in children younger than five years were illustrated in a prospective open-label multinational study that included 16 children with Hurler syndrome and four with Hurler-Scheie [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/150\">",
"     150",
"    </a>",
"    ]. Clinical improvements were noted in 94 percent of patients at week 52 (eg, improved hepatomegaly, left ventricular hypertrophy,",
"    <span class=\"nowrap\">",
"     apnea/hypopnea",
"    </span>",
"    index). The mean urine glycosaminoglycan level declined by approximately 50 percent by 13 weeks and was sustained thereafter.",
"   </p>",
"   <p>",
"    Enzyme replacement therapy in patients with MPS I does not appear to reverse corneal or optic disc changes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/146,151\">",
"     146,151",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     MPS II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzyme replacement therapy (ERT) for MPS II (Hunter syndrome) with recombinant human iduronate sulfatase (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36307?source=see_link\">",
"     idursulfase",
"    </a>",
"    , Elaprase&trade;) is licensed for use in the United States, Canada, Europe, and Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/152-154\">",
"     152-154",
"    </a>",
"    ]. Idursulfase (0.5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is administered in weekly infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/2,152\">",
"     2,152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical trials, patients (aged 5 to 31 years) treated with weekly infusions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36307?source=see_link\">",
"     idursulfase",
"    </a>",
"    for 53 weeks had a mean increase in the six-minute walk test and percent predicted forced vital capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/155\">",
"     155",
"    </a>",
"    ]. Treatment also decreased mean urinary GAG levels and liver and spleen volume. Anaphylactoid reactions were observed in some patients during infusion. The most common infusion-related reactions included headache, fever, cutaneous reaction, and hypertension. The frequency of infusion-related reactions decreased with time.",
"   </p>",
"   <p>",
"    Limited experience in children younger than five years of age suggests that early initiation of ERT may delay or prevent the development of irreversible manifestations of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/156,157\">",
"     156,157",
"    </a>",
"    ]. Although ERT appears to have no cognitive benefit in patients with a severe phenotype and cognitive impairment, it may lead to somatic improvement and, therefore, a limited trial may be warranted in some of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     MPS III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral enzyme replacement therapy of MPS III (Sanfilippo syndrome A&ndash;D) with primary brain disease is not expected to be beneficial because of the barrier to diffusion of the enzyme into the brain. In animal models and a human case report, intrathecal enzyme replacement therapy for other types of MPS (I, VI) has been associated with improved central nervous system GAG levels and clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/159-161\">",
"     159-161",
"    </a>",
"    ]. Intrathecal therapy remains experimental.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     Miglustat",
"    </a>",
"    , an inhibitor of glucosylceramide synthase that crosses the blood-brain barrier, did not",
"    <span class=\"nowrap\">",
"     improve/stabilize",
"    </span>",
"    behavior or decrease ganglioside levels in a randomized trial of 25 patients with MPS III [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     MPS VI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In May 2005, galsulfase (human recombinant N-acetylgalactosamine-4-sulfatase, rhASB, Naglazyme&trade;) was approved by the United States FDA as the first specific therapy for MPS VI (Maroteaux-Lamy syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/163\">",
"     163",
"    </a>",
"    ]. In preapproval randomized clinical trials, patients with severe manifestations of MPS VI who received weekly infusions of galsulfase for 24 weeks had reduced urinary GAG excretion and improved functional status [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/164-166\">",
"     164-166",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the phase III trial, patients in the treatment group had greater mean increases in the distance walked in 12 minutes and the number of stairs climbed in three minutes than those in the placebo group (a difference between groups of 92 m [95% CI 11-172 m] and 5.7 stairs per minute [95% CI -0.1-11.5], respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/167\">",
"     167",
"    </a>",
"    ]. In addition, in an open-label phase II trial, patients who received weekly infusions for 48 weeks responded with improved endurance and decreased pain compared with their baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the feline model of MPS VI, joint disease has been refractory to galsulfase because enzyme is unable to diffuse through the synovium to reach the articular cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/169\">",
"     169",
"    </a>",
"    ]. However, intraarticular administration successfully cleared glycosaminoglycans from chondrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/170\">",
"     170",
"    </a>",
"    ]. Slight reaccumulation of glycosaminoglycans was observed at the joint surface one month after injection; by two months, reaccumulation was extensive. These results suggest that, with further study, intermittent intraarticular administration of galsulfase may prove beneficial in the treatment of MPS VI joint disease in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy has been associated with some benefits in murine models of MPS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/16/35082/abstract/41,166,171-174\">",
"     41,166,171-174",
"    </a>",
"    ]. However, human studies have not been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mucopolysaccharidoses (MPS) are differentiated by their clinical features and age of presentation (",
"      <a class=\"graphic graphic_table graphicRef57733 \" href=\"UTD.htm?34/41/35485\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory complications of MPS may include central apnea, airway obstruction, sleep apnea, and frequent or chronic sinopulmonary infections or otitis media. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Respiratory complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac complications of MPS may include cardiomyopathy, endocardial fibroelastosis, valvular disease, vascular disease, and pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardiac complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skeletal and connective tissue complications of MPS may include dysostosis multiplex (the constellation of characteristic bony abnormalities) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75624 \" href=\"UTD.htm?6/35/6719\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52046 \" href=\"UTD.htm?18/41/19103\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50673 \" href=\"UTD.htm?40/2/41007\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51207 \" href=\"UTD.htm?23/40/24207\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63875 \" href=\"UTD.htm?18/6/18543\">",
"       image 5",
"      </a>",
"      ), spine abnormalities, genu valgum (knock knees), short stature, joint stiffness, ligamentous laxity, and inguinal and umbilical hernias. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Skeletal and connective tissue complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic complications of MPS may include developmental delay or neurologic decline, abnormal behavior, seizures (in Hunter and Sanfilippo syndromes), sleep disturbance, hydrocephalus, cervical cord compression, carpal tunnel syndrome, and diarrhea (thought to be related to abnormal motility). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Neurologic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ophthalmologic complications of MPS may include corneal clouding, glaucoma, optic neuropathy, and degeneration of the retina. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Ophthalmologic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific therapies for MPS include hematopoietic cell transplantation and enzyme replacement therapy (for MPS I [Hurler, Hurler-Scheie, and Scheie syndromes], MPS II [Hunter syndrome], MPS VI [Maroteaux-Lamy syndrome]). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Specific therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/1\">",
"      Semenza GL, Pyeritz RE. Respiratory complications of mucopolysaccharide storage disorders. Medicine (Baltimore) 1988; 67:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/2\">",
"      Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/3\">",
"      Stevens JM, Kendall BE, Crockard HA, Ransford A. The odontoid process in Morquio-Brailsford's disease. The effects of occipitocervical fusion. J Bone Joint Surg Br 1991; 73:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/4\">",
"      Jones AE, Croley TF. Morquio syndrome and anesthesia. Anesthesiology 1979; 51:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/5\">",
"      Ashraf J, Crockard HA, Ransford AO, Stevens JM. Transoral decompression and posterior stabilisation in Morquio's disease. Arch Dis Child 1991; 66:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/6\">",
"      Hughes DG, Chadderton RD, Cowie RA, et al. MRI of the brain and craniocervical junction in Morquio's disease. Neuroradiology 1997; 39:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/7\">",
"      Belani KG, Krivit W, Carpenter BL, et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J Pediatr Surg 1993; 28:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/8\">",
"      Brama I, Gay I, Feinmesser R, Springer C. Upper airway obstruction in Hunter syndrome. Int J Pediatr Otorhinolaryngol 1986; 11:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/9\">",
"      Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007; 120:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/10\">",
"      Yeung AH, Cowan MJ, Horn B, Rosbe KW. Airway management in children with mucopolysaccharidoses. Arch Otolaryngol Head Neck Surg 2009; 135:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/11\">",
"      Simonetti GD, Casaulta C, Vuissoz JM, et al. Recurrent unexplained episodes of facial cyanosis and shortness of breath in Hunter disease. J Pediatr 2009; 155:144, 144.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/12\">",
"      Bredenkamp JK, Smith ME, Dudley JP, et al. Otolaryngologic manifestations of the mucopolysaccharidoses. Ann Otol Rhinol Laryngol 1992; 101:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/13\">",
"      Leighton SE, Papsin B, Vellodi A, et al. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 2001; 58:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/14\">",
"      Morehead JM, Parsons DS. Tracheobronchomalacia in Hunter's syndrome. Int J Pediatr Otorhinolaryngol 1993; 26:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/15\">",
"      Walker RW, Darowski M, Morris P, Wraith JE. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia 1994; 49:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/16\">",
"      Walker PP, Rose E, Williams JG. Upper airways abnormalities and tracheal problems in Morquio's disease. Thorax 2003; 58:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/17\">",
"      Ruckenstein MJ, Macdonald RE, Clarke JT, Forte V. The management of otolaryngological problems in the mucopolysaccharidoses: a retrospective review. J Otolaryngol 1991; 20:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/18\">",
"      Baines D, Keneally J. Anaesthetic implications of the mucopolysaccharidoses: a fifteen-year experience in a children's hospital. Anaesth Intensive Care 1983; 11:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/19\">",
"      Kempthorne PM, Brown TC. Anaesthesia and the mucopolysaccharidoses: a survey of techniques and problems. Anaesth Intensive Care 1983; 11:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/20\">",
"      Moores C, Rogers JG, McKenzie IM, Brown TC. Anaesthesia for children with mucopolysaccharidoses. Anaesth Intensive Care 1996; 24:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/21\">",
"      Sj&oslash;gren P, Pedersen T, Steinmetz H. Mucopolysaccharidoses and anaesthetic risks. Acta Anaesthesiol Scand 1987; 31:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/22\">",
"      Suzuki M, Tsukagoshi M, Ashizawa N, Fukunaga A. [Anesthetic management of mucopolysaccharidosis]. Masui 1976; 25:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/23\">",
"      Linstedt U, Maier C, Joehnk H, Stephani U. Threatening spinal cord compression during anesthesia in a child with mucopolysaccharidosis VI. Anesthesiology 1994; 80:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/24\">",
"      Tobias JD. Anesthetic care for the child with Morquio syndrome: general versus regional anesthesia. J Clin Anesth 1999; 11:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/25\">",
"      Vas L, Naregal F. Failed epidural anaesthesia in a patient with Hurler's disease. Paediatr Anaesth 2000; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/26\">",
"      Walker RW, Allen DL, Rothera MR. A fibreoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway. Paediatr Anaesth 1997; 7:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/27\">",
"      Daly TM, Lorenz RG, Sands MS. Abnormal immune function in vivo in a murine model of lysosomal storage disease. Pediatr Res 2000; 47:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/28\">",
"      Braunlin EA, Harmatz PR, Scarpa M, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 2011; 34:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/29\">",
"      Donaldson MD, Pennock CA, Berry PJ, et al. Hurler syndrome with cardiomyopathy in infancy. J Pediatr 1989; 114:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/30\">",
"      Hayflick S, Rowe S, Kavanaugh-McHugh A, et al. Acute infantile cardiomyopathy as a presenting feature of mucopolysaccharidosis VI. J Pediatr 1992; 120:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/31\">",
"      Miller G, Partridge A. Mucopolysaccharidosis type VI presenting in infancy with endocardial fibroelastosis and heart failure. Pediatr Cardiol 1983; 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/32\">",
"      Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders--clinical and echocardiographic findings in 64 patients. Eur J Pediatr 1998; 157:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/33\">",
"      Wippermann CF, Beck M, Schranz D, et al. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 1995; 154:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/34\">",
"      Nelson J, Shields MD, Mulholland HC. Cardiovascular studies in the mucopolysaccharidoses. J Med Genet 1990; 27:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/35\">",
"      Masuda H, Morishita Y, Taira A, Kuriyama M. Aortic stenosis associated with Scheie's syndrome. Report of successful valve replacement. Chest 1993; 103:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/36\">",
"      Butman SM, Karl L, Copeland JG. Combined aortic and mitral valve replacement in an adult with Scheie's disease. Chest 1989; 96:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/37\">",
"      Tan CT, Schaff HV, Miller FA Jr, et al. Valvular heart disease in four patients with Maroteaux-Lamy syndrome. Circulation 1992; 85:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/38\">",
"      Taylor DB, Blaser SI, Burrows PE, et al. Arteriopathy and coarctation of the abdominal aorta in children with mucopolysaccharidosis: imaging findings. AJR Am J Roentgenol 1991; 157:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/39\">",
"      Braunlin EA, Hunter DW, Krivit W, et al. Evaluation of coronary artery disease in the Hurler syndrome by angiography. Am J Cardiol 1992; 69:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/40\">",
"      Brosius FC 3rd, Roberts WC. Coronary artery disease in the Hurler syndrome. Qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children. Am J Cardiol 1981; 47:649.",
"     </a>",
"    </li>",
"    <li>",
"     Neufeld EF, Muenzer J. The metabolic and molecular bases of inherited disease, Scriver C, Beaudet AL, Valle D, Sly W (Eds), McGraw-Hill, New York 2001. p.3421.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/42\">",
"      Instability of the upper cervical spine. Skeletal Dysplasia Group. Arch Dis Child 1989; 64:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/43\">",
"      Schmidt H, Ullrich K, von Lengerke HJ, et al. Radiological findings in patients with mucopolysaccharidosis I H/S (Hurler-Scheie syndrome). Pediatr Radiol 1987; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/44\">",
"      Langer LO Jr, Carey LS. The roentgenographic features of the KS mucopolysaccharidosis of Morquio (Morquio-Brailsford's disease). Am J Roentgenol Radium Ther Nucl Med 1966; 97:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/45\">",
"      Tassinari E, Boriani L, Traina F, et al. Bilateral total hip arthroplasty in Morquio-Brailsford's syndrome: a report of two cases. Chir Organi Mov 2008; 92:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/46\">",
"      Nelson J, Thomas PS. Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part III: Odontoid dysplasia. Clin Genet 1988; 33:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/47\">",
"      Thomas SL, Childress MH, Quinton B. Hypoplasia of the odontoid with atlanto-axial subluxation in Hurler's syndrome. Pediatr Radiol 1985; 15:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/48\">",
"      Levin TL, Berdon WE, Lachman RS, et al. Lumbar gibbus in storage diseases and bone dysplasias. Pediatr Radiol 1997; 27:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/49\">",
"      Piccirilli CB, Chadduck WM. Cervical kyphotic myelopathy in a child with Morquio syndrome. Childs Nerv Syst 1996; 12:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/50\">",
"      Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis 1996; 19:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/51\">",
"      Odunusi E, Peters C, Krivit W, Ogilvie J. Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention. J Pediatr Orthop 1999; 19:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/52\">",
"      Gardner CJ, Robinson N, Meadows T, et al. Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H). J Inherit Metab Dis 2011; 34:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/53\">",
"      Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr 2011; 100:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/54\">",
"      Schulze-Frenking G, Jones SA, Roberts J, et al. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 2011; 34:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/55\">",
"      Simonaro CM, Ge Y, Eliyahu E, et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 2010; 107:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/56\">",
"      Simonaro CM, D'Angelo M, He X, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008; 172:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/57\">",
"      Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005; 57:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/58\">",
"      Kopits SE. Orthopedic complications of dwarfism. Clin Orthop Relat Res 1976; :153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/59\">",
"      Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995; 72:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/60\">",
"      Cleary MA, Wraith JE. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr 1995; 84:337.",
"     </a>",
"    </li>",
"    <li>",
"     Kakkis ED, Neufeld EF. The mucopolysaccharidoses. In: Principles of child neurology, Berg BO (Ed), McGraw-Hill, New York 1996. p.1141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/62\">",
"      Gabrielli O, Salvolini U, Maricotti M, et al. Cerebral MRI in two brothers with mucopolysaccharidosis type I and different clinical phenotypes. Neuroradiology 1992; 34:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/63\">",
"      Shimoda-Matsubayashi S, Kuru Y, Sumie H, et al. MRI findings in the mild type of mucopolysaccharidosis II (Hunter's syndrome). Neuroradiology 1990; 32:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/64\">",
"      Taccone A, Tortori Donati P, Marzoli A, et al. Mucopolysaccharidosis: thickening of dura mater at the craniocervical junction and other CT/MRI findings. Pediatr Radiol 1993; 23:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/65\">",
"      Afifi AK, Sato Y, Waziri MH, Bell WE. Computed tomography and magnetic resonance imaging of the brain in Hurler's disease. J Child Neurol 1990; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/66\">",
"      Johnson MA, Desai S, Hugh-Jones K, Starer F. Magnetic resonance imaging of the brain in Hurler syndrome. AJNR Am J Neuroradiol 1984; 5:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/67\">",
"      Parsons VJ, Hughes DG, Wraith JE. Magnetic resonance imaging of the brain, neck and cervical spine in mild Hunter's syndrome (mucopolysaccharidoses type II). Clin Radiol 1996; 51:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/68\">",
"      Wassman ER, Johnson K, Shapiro LJ, et al. Postmortem findings in the Hurler-Scheie syndrome (mucopolysaccharidosis I-H/S). Birth Defects Orig Artic Ser 1982; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/69\">",
"      Barone R, Nigro F, Triulzi F, et al. Clinical and neuroradiological follow-up in mucopolysaccharidosis type III (Sanfilippo syndrome). Neuropediatrics 1999; 30:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/70\">",
"      Peters C, Shapiro EG, Krivit W. Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr Transplant 1998; 2:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/71\">",
"      Nidiffer FD, Kelly TE. Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study. J Ment Defic Res 1983; 27 (Pt 3):185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/72\">",
"      Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995; 18:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/73\">",
"      Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983; 25:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/74\">",
"      van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 1981; 20:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/75\">",
"      Wraith JE, Danks DM, Rogers JG. Mild Sanfilippo syndrome: a further cause of hyperactivity and behavioural disturbance. Med J Aust 1987; 147:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/76\">",
"      Bax MC, Colville GA. Behaviour in mucopolysaccharide disorders. Arch Dis Child 1995; 73:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/77\">",
"      Cleary MA, Wraith JE. Management of mucopolysaccharidosis type III. Arch Dis Child 1993; 69:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/78\">",
"      Colville GA, Watters JP, Yule W, Bax M. Sleep problems in children with Sanfilippo syndrome. Dev Med Child Neurol 1996; 38:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/79\">",
"      Kriel RL, Hauser WA, Sung JH, Posalaky Z. Neuroanatomical and electroencephalographic correlations in Sanfilippo syndrome, type A. Arch Neurol 1978; 35:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/80\">",
"      Shinnar S, Singer HS, Valle D. Acute hydrocephalus Hurler's syndrome. Am J Dis Child 1982; 136:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/81\">",
"      Van Aerde J, Campbell A. Hydrocephalus and shunt placement. Am J Dis Child 1983; 137:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/82\">",
"      Sheridan M, Johnston I. Hydrocephalus and pseudotumour cerebri in the mucopolysaccharidoses. Childs Nerv Syst 1994; 10:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/83\">",
"      Goldberg MF, Scott CI, McKusick VA. Hydrocephalus and papilledema in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Am J Ophthalmol 1970; 69:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/84\">",
"      van Aerde J, Plets C, Van der Hauwaert L. Hydrocephalus in Hunter Syndrome. Acta Paediatr Belg 1981; 34:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/85\">",
"      Muenzer J. Mucopolysaccharidoses. Adv Pediatr 1986; 33:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/86\">",
"      Collins ML, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology 1990; 97:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/87\">",
"      Kaufman HH, Rosenberg HS, Scott CI, et al. Cervical myelopathy due to dural compression in mucopolysaccharidosis. Surg Neurol 1982; 17:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/88\">",
"      Paulson GW, Meagher JN, Burkhart J. Spinal pachymeningitis secondary to mucopolysaccharidosis. Case report. J Neurosurg 1974; 41:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/89\">",
"      Kachur E, Del Maestro R. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery 2000; 47:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/90\">",
"      Young R, Kleinman G, Ojemann RG, et al. Compressive myelopathy in Maroteaux-Lamy syndrome: clinical and pathological findings. Ann Neurol 1980; 8:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/91\">",
"      Banna M, Hollenberg R. Compressive meningeal hypertrophy in mucopolysaccharidosis. AJNR Am J Neuroradiol 1987; 8:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/92\">",
"      O'Brien DP, Cowie RA, Wraith JE. Cervical decompression in mild mucopolysaccharidosis type II (Hunter syndrome). Childs Nerv Syst 1997; 13:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/93\">",
"      Brill CB, Rose JS, Godmilow L, et al. Spastic quadriparesis due to C1-C2 subluxation in Hurler syndrome. J Pediatr 1978; 92:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/94\">",
"      Pizzutillo PD, Osterkamp JA, Scott CI Jr, Lee MS. Atlantoaxial instability in mucopolysaccharidosis type VII. J Pediatr Orthop 1989; 9:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/95\">",
"      Tandon V, Williamson JB, Cowie RA, Wraith JE. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br 1996; 78:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/96\">",
"      Ransford AO, Crockard HA, Stevens JM, Modaghegh S. Occipito-atlanto-axial fusion in Morquio-Brailsford syndrome. A ten-year experience. J Bone Joint Surg Br 1996; 78:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/97\">",
"      Lipson SJ. Dysplasia of the odontoid process in Morquio's syndrome causing quadriparesis. J Bone Joint Surg Am 1977; 59:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/98\">",
"      Boor R, Miebach E, Br&uuml;hl K, Beck M. Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses. Neuropediatrics 2000; 31:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/99\">",
"      Mikles M, Stanton RP. A review of Morquio syndrome. Am J Orthop (Belle Mead NJ) 1997; 26:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/100\">",
"      Gulati MS, Agin MA. Morquio syndrome: a rehabilitation perspective. J Spinal Cord Med 1996; 19:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/101\">",
"      Van Heest AE, House J, Krivit W, Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg Am 1998; 23:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/102\">",
"      Haddad FS, Jones DH, Vellodi A, et al. Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses. J Bone Joint Surg Br 1997; 79:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/103\">",
"      Gschwind C, Tonkin MA. Carpal tunnel syndrome in children with mucopolysaccharidosis and related disorders. J Hand Surg Am 1992; 17:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/104\">",
"      Wraith JE, Alani SM. Carpal tunnel syndrome in the mucopolysaccharidoses and related disorders. Arch Dis Child 1990; 65:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/105\">",
"      Yuen A, Dowling G, Johnstone B, et al. Carpal tunnel syndrome in children with mucopolysaccaridoses. J Child Neurol 2007; 22:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/106\">",
"      Norman-Taylor F, Fixsen JA, Sharrard WJ. Hunter's syndrome as a cause of childhood carpal tunnel syndrome: a report of three cases. J Pediatr Orthop B 1995; 4:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/107\">",
"      Bona I, Vial C, Brunet P, et al. Carpal tunnel syndrome in Mucopolysaccharidoses. A report of four cases in child. Electromyogr Clin Neurophysiol 1994; 34:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/108\">",
"      Cruz Mart&iacute;nez A, Arpa J. Carpal tunnel syndrome in childhood: study of 6 cases. Electroencephalogr Clin Neurophysiol 1998; 109:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/109\">",
"      MacDougal B, Weeks PM, Wray RC Jr. Median nerve compression and trigger finger in the mucopolysaccharidoses and related diseases. Plast Reconstr Surg 1977; 59:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/110\">",
"      Pronicka E, Tylki-Szymanska A, Kwast O, et al. Carpal tunnel syndrome in children with mucopolysaccharidoses: needs for surgical tendons and median nerve release. J Ment Defic Res 1988; 32 ( Pt 1):79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/111\">",
"      Karpati G, Carpenter S, Eisen AA, et al. Multiple peripheral nerve entrapments. An unusual phenotypical variant of the Hunter syndrome (mucopolysaccharidosis II) in a family. Arch Neurol 1974; 31:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/112\">",
"      Swift TR, McDonald TF. Peripheral nerve involvement in Hunter syndrome (mucopolysaccharidosis II). Arch Neurol 1976; 33:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/113\">",
"      Haddad FS, Hill RA, Jones DH. Triggering in the mucopolysaccharidoses. J Pediatr Orthop B 1998; 7:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/114\">",
"      Elsner B. Ultrastructure of the rectal wall in Hunter's syndrome. Gastroenterology 1970; 58:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/115\">",
"      Schumacher RG, Brzezinska R, Schulze-Frenking G, Pitz S. Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI. Pediatr Radiol 2008; 38:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/116\">",
"      Krivit W, Sung JH, Shapiro EG, Lockman LA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 1995; 4:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/117\">",
"      Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol 2010; 47:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/118\">",
"      Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998; 91:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/119\">",
"      Guffon N, Souillet G, Maire I, et al. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998; 133:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/120\">",
"      Vellodi A, Young EP, Cooper A, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 1997; 76:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/121\">",
"      Peters C, Balthazor M, Shapiro EG, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996; 87:4894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/122\">",
"      Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 1993; 46:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/123\">",
"      Hopwood JJ, Vellodi A, Scott HS, et al. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis 1993; 16:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/124\">",
"      Malm G, Gustafsson B, Berglund G, et al. Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatr 2008; 97:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/125\">",
"      Aldenhoven M, Boelens JJ, de Koning TJ. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 2008; 14:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/126\">",
"      Grigull L, Sykora KW, Tenger A, et al. Variable disease progression after successful stem cell transplantation: prospective follow-up investigations in eight patients with Hurler syndrome. Pediatr Transplant 2011; 15:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/127\">",
"      Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology 1998; 105:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/128\">",
"      Field RE, Buchanan JA, Copplemans MG, Aichroth PM. Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J Bone Joint Surg Br 1994; 76:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/129\">",
"      Masterson EL, Murphy PG, O'Meara A, et al. Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Pediatr Orthop 1996; 16:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/130\">",
"      Hirth A, Berg A, Greve G. Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis 2007; 30:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/131\">",
"      Cox-Brinkman J, Boelens JJ, Wraith JE, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 2006; 38:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/132\">",
"      Wynn RF, Mercer J, Page J, et al. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr 2009; 154:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/133\">",
"      Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr 2013; 162:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/134\">",
"      Vellodi A, Young E, Cooper A, et al. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999; 22:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/135\">",
"      McKinnis EJ, Sulzbacher S, Rutledge JC, et al. Bone marrow transplantation in Hunter syndrome. J Pediatr 1996; 129:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/136\">",
"      Krivit W. Maroteaux-Lamy syndrome (mucopolysaccharidosis VI): Treatment by allogeneic bone marrow transplantation in 6 patients and potential for autotransplantation bone marrow gene insertion. Int Pediatr 1992; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/137\">",
"      Yamada Y, Kato K, Sukegawa K, et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant 1998; 21:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/138\">",
"      Guffon N, Bertrand Y, Forest I, et al. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 2009; 154:733.",
"     </a>",
"    </li>",
"    <li>",
"     Krivit W, Whitley CB, Chang P, et al. Lysosomal storage diseases treated by bone marrow transplantation: Review of 21 patients. In: Bone marrow transplantation in children, Johnson E, Pochedly C (Eds), Raven Press, New York 1990. p.261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/140\">",
"      Lee V, Li CK, Shing MM, et al. Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant 2000; 26:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/141\">",
"      Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/142\">",
"      Boelens JJ, Wynn RF, O'Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007; 40:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/143\">",
"      Dietz HC. New therapeutic approaches to mendelian disorders. N Engl J Med 2010; 363:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/144\">",
"      Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/145\">",
"      Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/146\">",
"      Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007; 90:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/147\">",
"      Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2010; 125:e183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/148\">",
"      Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/149\">",
"      Kakavanos R, Turner CT, Hopwood JJ, et al. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003; 361:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/150\">",
"      Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007; 120:e37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/151\">",
"      Pitz S, Ogun O, Bajbouj M, et al. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience. Arch Ophthalmol 2007; 125:1353.",
"     </a>",
"    </li>",
"    <li>",
"     FDA News. FDA approves first treatment for Hunter syndrome. July 24, 2006. www.fda.gov/bbs/topics/NEWS/2006/NEW01418.html (Accessed on August 01, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/153\">",
"      Muenzer J, Martins AM. Hunter syndrome: to treat or not to treat. Acta Paediatr Suppl 2008; 97:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/154\">",
"      da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev 2011; :CD008185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/155\">",
"      Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/156\">",
"      Muenzer J, Beck M, Giugliani R, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011; 13:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/157\">",
"      Tylki-Szymanska A, Jurecka A, Zuber Z, et al. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr 2012; 101:e42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/158\">",
"      Muenzer J, Bodamer O, Burton B, et al. The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr 2012; 171:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/159\">",
"      Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007; 91:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/160\">",
"      Auclair D, Finnie J, White J, et al. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol Genet Metab 2010; 99:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/161\">",
"      Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 2008; 146A:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/162\">",
"      Guffon N, Bin-Dorel S, Decullier E, et al. Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. J Pediatr 2011; 159:838.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Center for Drug Evaluation and Research. www.accessdata.fda.gov/scripts/cder/drugsatfda (Accessed on September 26, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/164\">",
"      Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144:574.",
"     </a>",
"    </li>",
"    <li>",
"     Naglazyme&trade; (galsulfase) product label. Biomarin Pharmaceutical Inc, Novato, CA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/166\">",
"      Stein CS, Ghodsi A, Derksen T, Davidson BL. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol 1999; 73:3424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/167\">",
"      Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006; 148:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/168\">",
"      Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005; 115:e681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/169\">",
"      Crawley AC, Niedzielski KH, Isaac EL, et al. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 1997; 99:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/170\">",
"      Auclair D, Hein LK, Hopwood JJ, Byers S. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval. Pediatr Res 2006; 59:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/171\">",
"      Watson GL, Sayles JN, Chen C, et al. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther 1998; 5:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/172\">",
"      Sands MS, Wolfe JH, Birkenmeier EH, et al. Gene therapy for murine mucopolysaccharidosis type VII. Neuromuscul Disord 1997; 7:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/173\">",
"      Ohashi T, Watabe K, Uehara K, et al. Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci U S A 1997; 94:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/16/35082/abstract/174\">",
"      Bosch A, Perret E, Desmaris N, Heard JM. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 2000; 1:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2932 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35082=[""].join("\n");
var outline_f34_16_35082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESPIRATORY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Central apnea from cord compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sinopulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CARDIAC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Valvular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SKELETAL AND CONNECTIVE TISSUE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dysostosis multiplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Spine abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Odontoid hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Subluxation and kyphoscoliosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Genu valgum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Short stature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Joint stiffness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ligamentous laxity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NEUROLOGIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Developmental delay and neurologic decline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Abnormal behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Sleep disturbance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cervical cord compression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Pachymeningitis cervicalis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - C1&ndash;C2 subluxation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      OPHTHALMOLOGIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SPECIFIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Cord blood transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Enzyme replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - MPS I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - MPS II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - MPS III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - MPS VI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2932|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/35/6719\" title=\"diagnostic image 1\">",
"      Dysostosis skull radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/41/19103\" title=\"diagnostic image 2\">",
"      Dysostosis lumbar vertebrae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/2/41007\" title=\"diagnostic image 3\">",
"      MPS I chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/40/24207\" title=\"diagnostic image 4\">",
"      MPS I forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/6/18543\" title=\"diagnostic image 5\">",
"      Dysostosis metacarpal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/24/18817\" title=\"diagnostic image 6\">",
"      Scheie brain MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/37/15952\" title=\"diagnostic image 7\">",
"      Hurler brain MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/24/18816\" title=\"diagnostic image 8A\">",
"      MPS I cord compression A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/13/9427\" title=\"diagnostic image 8B\">",
"      MPS I cord compression B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2932|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/21/41311\" title=\"picture 1\">",
"      Gibbus deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/13/2271\" title=\"picture 2\">",
"      MPS I hand",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/41/35485\" title=\"table 1\">",
"      Biochem clin feat MPS A",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6199?source=related_link\">",
"      Approach to the child with knock-knees",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=related_link\">",
"      Management of obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9801?source=related_link\">",
"      Mechanisms and predisposing factors for sleep related breathing disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32822?source=related_link\">",
"      Surgery for carpal tunnel syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_16_35083="Classification and characterization of proteinuria types";
var content_f34_16_35083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F85791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F85791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification and characterization of proteinuria types",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Classification of proteinuria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical level of proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient proteinuria",
"       </td>",
"       <td>",
"        Fever, heavy exercise, vasopressor infusion, albumin infusion",
"       </td>",
"       <td>",
"        &lt;1 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent proteinuria - orthostatic proteinuria",
"       </td>",
"       <td>",
"        Uncommon over age 30 years, may occur in 2 to 5 percent of adolescents",
"       </td>",
"       <td>",
"        &lt;1 to 2&nbsp;g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent proteinuria - overflow proteinuria",
"       </td>",
"       <td>",
"        Myeloma (monoclonal light chains), Hemolysis (hemoglobinuria), Rhabdomyolysis (myoglobinuria)",
"       </td>",
"       <td>",
"        Variable, could be nephrotic range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent proteinuria - glomerular proteinuria",
"       </td>",
"       <td>",
"        Primary glomerular diseases, secondary glomerular diseases, diabetic nephropathy, hypertensive nephrosclerosis",
"       </td>",
"       <td>",
"        Variable, often nephrotic range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent proteinuria - tubulointerstitial proteinuria",
"       </td>",
"       <td>",
"        Heavy metal intoxications, autoimmune or allergic interstitial inflammation, medication-induced interstitial injury",
"       </td>",
"       <td>",
"        &lt;3 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-renal proteinuria",
"       </td>",
"       <td>",
"        Urinary tract infections, nephrolithiasis, genito-urinary tumor",
"       </td>",
"       <td>",
"        &lt;1 g/day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35083=[""].join("\n");
var outline_f34_16_35083=null;
var title_f34_16_35084="Treatment of giardiasis";
var content_f34_16_35084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of giardiasis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Dosage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adults",
"       </td>",
"       <td class=\"subtitle2\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tinidazole",
"       </td>",
"       <td>",
"        2 grams orally, single dose",
"       </td>",
"       <td>",
"        50 mg/kg orally, single dose (maximum dose 2 grams)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metronidazole",
"       </td>",
"       <td>",
"        500&nbsp;mg orally twice daily, OR 250 mg orally three times per day; duration 5 to 7 days",
"       </td>",
"       <td>",
"        5 to 10&nbsp;mg/kg orally three times per day for 7 days (maximum 250 mg per dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitazoxanide",
"       </td>",
"       <td>",
"        500 mg orally two times per day for three days",
"       </td>",
"       <td>",
"        <p>",
"         Age 1-3 years: 100 mg orally two times per day for 3 days",
"        </p>",
"        <p>",
"         Age 4-11 years: 200 mg orally two times per day for 3 days",
"        </p>",
"        <p>",
"         Age over 11 years: Same as adult dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Alternative agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Albendazole",
"       </td>",
"       <td>",
"        <p>",
"         400 mg orally once daily for 5 days",
"        </p>",
"       </td>",
"       <td>",
"        10 to 15 mg/kg orally once daily for 5 days (maximum 400 mg per dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mebendazole",
"       </td>",
"       <td>",
"        <p>",
"         200 mg orally three times per day for 5 days",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         200 mg orally three times per day for 5 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paromomycin*",
"       </td>",
"       <td>",
"        10 mg/kg orally three times per day for 5 to 10 days",
"       </td>",
"       <td>",
"        <p>",
"         10 mg/kg orally three times per day for 5 to 10 days",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Furazolidone",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg orally four times per day for 7 to 10 days",
"       </td>",
"       <td>",
"        1.5 mg/kg orally four times per day for 7 to 10 days (maximum 100 mg per dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quinacrine",
"       </td>",
"       <td>",
"        100 mg orally three times per day for 5 days",
"       </td>",
"       <td>",
"        2 mg/kg orally three times per day for&nbsp;5 days (maximum 100 mg per dose)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    See text for additional information regarding choice of therapy, approach to recurrent infection, and availability.",
"    <div class=\"footnotes\">",
"     * Poor intestinal absorption; may be useful for treatment of giardiasis in pregnancy.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Potentially significant drug and food interactions with use greater than 5 days due to monoamine oxidase inhibition. For additional information (see \"Furazolidone: Drug information\" section 'Drug Interactions').",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35084=[""].join("\n");
var outline_f34_16_35084=null;
var title_f34_16_35085="USPSTF grade AB recommendations";
var content_f34_16_35085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adult screening and prevention recommendations of USPSTF (2011-2012) A and B recommendations (good and fair evidence of effectiveness)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Service",
"       </td>",
"       <td class=\"subtitle1\">",
"        Target population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for abdominal aortic aneurysm",
"       </td>",
"       <td>",
"        Ever-smoking men ages 65 to 75 years: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirin for primary prevention of cardiovascular events",
"       </td>",
"       <td>",
"        Pregnant women: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Screening for dyslipidemia",
"       </td>",
"       <td>",
"        Average-risk men &gt;35: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased-risk: men 20 to 35, women &gt;20: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screen with TC and HDL: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for hypertension",
"       </td>",
"       <td>",
"        Adults ages 18+: A",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for breast cancer with mammography (biennial)",
"       </td>",
"       <td>",
"        Women ages 50 to 75: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Family history risk assessment and referral for BRCA mutation counseling concerning breast and ovarian cancer susceptibility",
"       </td>",
"       <td>",
"        Women whose family history is associated with an increased risk for deleterious mutations in BRCA 1 or BRCA 2: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discussion of chemoprevention of breast cancer",
"       </td>",
"       <td>",
"        Women at increased risk of breast cancer and decreased risk of adverse events: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for cervical cancer with Pap smear (every three years)",
"       </td>",
"       <td>",
"        Women ages 21 to 65 who have been sexually active and have a cervix: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for colorectal cancer",
"       </td>",
"       <td>",
"        Adults ages 50 to 75: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Counseling to prevent skin cancer",
"       </td>",
"       <td>",
"        Adolescents, young adults with fair skin: B",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for depression",
"       </td>",
"       <td>",
"        Adults within a system of care: B",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for type 2 diabetes",
"       </td>",
"       <td>",
"        Adults with blood pressure &ge;135/80: B",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fall prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exercise or physical activity and vitamin D supplementation",
"       </td>",
"       <td>",
"        Community-dwelling adults age &ge;65 at increased risk for falls: B",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lifestyle-related problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intensive behavioral dietary counseling",
"       </td>",
"       <td>",
"        Adults with hyperlipidemia or other risk factors for CVD: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for obesity with intensive counseling and behavioral interventions",
"       </td>",
"       <td>",
"        Adults: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Screen for tobacco use and provide tobacco cessation intervention",
"       </td>",
"       <td>",
"        Adults: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnant women: A",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Sexually transmitted infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Behavioral counseling to prevent sexually transmitted diseases",
"       </td>",
"       <td>",
"        Adolescents and adults at increased risk: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for chlamydia",
"       </td>",
"       <td>",
"        Sexually-active women &le;25 years; others at increased risk: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for gonorrhea",
"       </td>",
"       <td>",
"        Women at increased risk: B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Screening for HIV",
"       </td>",
"       <td>",
"        Pregnant women: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adolescents and adults at increased risk: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for syphilis",
"       </td>",
"       <td>",
"        Increased risk and pregnant women: A",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Substance abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for alcohol misuse",
"       </td>",
"       <td>",
"        Adults: B",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for asymptomatic bacteriuria",
"       </td>",
"       <td>",
"        Pregnant women: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for hepatitis B",
"       </td>",
"       <td>",
"        Pregnant women: A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for osteoporosis",
"       </td>",
"       <td>",
"        Women ages 65+ and women 60 to 64 with risk factors: B",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A: Good evidence that intervention improves patient outcome and provides net benefit.",
"    <br/>",
"    B: Fair evidence that intervention improves patient outcome and provides net benefit.",
"    <div class=\"footnotes\">",
"     USPSTF: United States Preventive Services Task Force; CVD: cardiovascular disease; TC: total cholesterol; HDL: high-density lipoprotein.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35085=[""].join("\n");
var outline_f34_16_35085=null;
var title_f34_16_35086="Rx MS moderate severe sx II";
var content_f34_16_35086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: Management strategy for patients with moderate to severe mitral stenosis (MS) and moderate to severe symptoms (NYHA functional class III to IV) - Part II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 469px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The committee recognizes that there may be variability in the measurement of MVA and that the mean transmitral gradient, PAWA, and PASP should also be taken into consideration.",
"     <br>",
"      &bull; There is controversy as to whether patients with severe pulmonary hypertension (pulmonary artery systolic pressure &gt;60-80 mmHg) should undergo mitral valve replacement to prevent right ventricular failure.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35086=[""].join("\n");
var outline_f34_16_35086=null;
var title_f34_16_35087="Gastric component of the LES";
var content_f34_16_35087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Gastric component of the LES",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The proximal margin of the lower esophageal sphincter (LES) extends up to and a short distance proximal to the squamocolumnar junction (not shown). The distal margin of the LES is more difficult to define but careful anatomic studies suggest that it is composed of elements of the gastric musculature, the opposing clasp and sling fibers of the gastric cardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Liebermann-Meffert D, Allg&ouml;wer M, Schmid P, Blum AL. Muscular equivalent of the lower esophageal sphincter. Gastroenterology 1979; 76:31.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_16_35087=[""].join("\n");
var outline_f34_16_35087=null;
